Abstract Funding Sources*

AGA Oral and Poster Presentations at DDW® 2015

AGA Institute
4930 Del Ray Avenue
Bethesda, MD 20814

301.654.2055 (National Office)
301.654.3978 (Fax)
www.gastro.org

* Information contained in this report is current as of March 30, 2015
AGA Oral Presentations
1. Potential Effectiveness and Cost-Effectiveness *(4*)

2. Direct Costs in Patients With Celiac Disease *(3*) Design, conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content. Medical writing support was provided by Cathryn M. Carter, MS, of Arbor Communications, Inc.; this support was funded by a competitive, peer-reviewed grant from the Janssen Future Leaders in IBD program. Janssen Canada had no financial support for the study were provided by AbbVie.

3. Cost per clinical outcomes with biologics *(3*) The study was funded by Takeda Pharmaceuticals International, Inc.

4. Six-Food Elimination Diet or Topical Steroids *(2*)

5. Zinc Intake and Risk of Crohn’s disease *(2*)

6. The Influence of Rural/Urban Environment *(3*)*(4*) This study was funded by a competitive, peer-reviewed grant from the Janssen Future Leaders in IBD program. Janssen Canada had no influence on the study design, analysis, or reporting of the results.

7. Statins Associated with Decreased Risk of New Onset IBD *(5*)

8. Receiving corticosteroids therapy is associated with a poor outcome *(5*)

9. Extraintestinal Manifestations of Inflammatory Bowel Disease *(2*)

10. No Difference in Ulcerative Colitis Colectomy Outcome *(4*)

11. Inhibition of Kras activation ameliorates *(2*)*(6) *(4*)

12. Role of CDH1, TGFβR2, and KRAS mutations *(2*)

13. DARPP32: a bridge between pro-inflammatory signaling *(2*)

14. EB13 Regulates the Development of Atrophic Gastritis *(7*) *(2) *(4)

15. Restoration of Notch1 receptor expression *(2*)

16. Loss of TFF1 promotes H. pylori-induced *(2*)

17. Increased Expression of LRRK2, a Susceptibility Gene *(2*) *(4)

18. NOD2-dependent IL-33 expression is an important mechanism *(7) *(2)

19. Role and species-specific expression of colon T-Cell *(2*)

20. IL-33 signaling augments epithelial barrier function *(2*) *(4)

21. Genetic Modulation of PPARγ Phosphorylation *(2) *(4)

22. IL-34 antibody ameliorates experimental colitis *(5*)

23. Schlafen 12 regulates human enterocyte differentiation *(2*)

24. Modeling Familial Adenomatous Polyposis *(2*)

25. Intestinal epithelial cell specific deletion of Nfkb2 *(4*)

26. The cellular plasticity of fetal and adult intestinal epithelium *(2*)

27. Neutral Na+ Absorption and Fluid/Anterior Secretion *(2*)

28. Bile Acids Regulate Colonic Stem Cell Functions *(2*)

29. Lacking vitamin D receptor leads to intestinal dysbiosis *(6) *(4)

30. Role of Long Polar Fimbriae in the interactions *(5*)

31. Helicobacter sanguinii, a novel helicobacter *(2*)

32. TIR-domain containing adapter-inducing interferon-β *(2*)

33. Intestinal Highly-mobility group box1 (HMG1) protects *(2*)

34. Human Intestinal Epithelial Response *(2*)

35. Leptin is required for glucose homeostasis *(2*) *(4)

36. Nutrigenetic-guided dietary intervention and weight loss *(3) *(7) *(2)

37. One-year follow-up and physiological alterations *(4) *(3) Apollo Endosurgery

38. Effect of the GLP-1 analogue Exenatide *(2*)

39. Duodenal spinal nerves expressing the vanilloid receptor TRPV1 *(4) *(3)

40. Effect of Roux-en-Y gastric bypass and hypocaloric diet *(2*)

41. Cathepsin D expression in pancreatic ductal *(4) *(2)

42. Effect of Immunosuppressive Therapies *(5*)

43. Long-Term Outcomes of IPMNs with Consensus Guidelines Criteria *(5*)

44. Elevated Neutrophil-Lymphocyte Ratio at Diagnosis *(5*)

45. Rapid Growth Rates of Suspected Pancreatic Cyst *(5*)

46. Aurora kinase-A mediates acquired resistance *(2*)

47. Terpinen-4-ol: A novel and promising therapeutic agent *(4*)

48. Synthetic lethal interaction between oncogenic KRAS *(2*)

49. Reversal of mutant KRAS-mediated apoptosis *(2*)


51. Targeted Photodynamic Nanoconjugate Therapy *(2*)

52. Persistent low-grade dysplasia in Barrett’s esophagus *(5*)

53. Six Year Disease Durability Outcomes on Patients *(5*)

54. Evaluation of a minimally-invasive cytosponge esophageal *(3) *(2) Covidien GI Solutions

55. Detection of Barrett’s Dysplasia by Assay *(4) *(3) Exact Sciences

56. Evaluation of TP53 mutations on Barrett’s epithelium *(4*)

57. SNORA42 – An oncogenic small nucleolar RNA *(2*)

58. Mutational Analysis of Circulating Tumor Cell Subpopulations *(5*)

59. Nanoarray sensor technology-based volatile marker *(4) *(2) EuroNanoMed II VOLGACORE funding

60. A short isoform of DCLK1 is a novel prognostic marker *(2*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CATA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Abstract Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>241</td>
<td>Increased Reflux Severity on Impedance...[5*]</td>
<td><em>(6</em>)</td>
</tr>
<tr>
<td>242</td>
<td>A combination of fasting serum gastrin concentration...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>243</td>
<td>Comparison of Two Studies of the Upper Esophageal Sphincter...[3*] Somna Therapeutics, L.L.C.</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>244</td>
<td>Enhanced stimulated stress hormone response...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>245</td>
<td>Evidence for a new mechanism underlying persistent visceral...[2*][4]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>246</td>
<td>A double-blind crossover study using Magnetic Resonance Imaging...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>247</td>
<td>Zonulin Serum Levels are Increased...[4*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>248</td>
<td>Candidate Genes, Mucosal mRNA and Protein Expression...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>249</td>
<td>ErbB4 expression on macrophages...[2*][6]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>250</td>
<td>Large deletion in the EPCAM gene...[4*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>251</td>
<td>Celiac Disease histopathology recapitulates...[6*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>252</td>
<td>Crosstalk between PKD1 and β-catenin signaling pathways...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>253</td>
<td>TSC2/mTORC1 signaling controls Paneth...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>254</td>
<td>Methyl donor deficiency induces small intestinal crypt hypertrophy...[6*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>255</td>
<td>High unsaturated fat diets and unsaturated visceral fat...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>256</td>
<td>p62/SQSTM1 in pancreatitis is regulated...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>257</td>
<td>Basal autophagy plays an important role...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>258</td>
<td>Exosomes derived from pancreatic stellate cells...[4*][2]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>259</td>
<td>Intrapancreatic Transforming Growth Factor betal...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>260</td>
<td>The impact of Bcl-xL upregulation...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>261</td>
<td>Enteric resident bacteria induce colonic...[6*][2]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>262</td>
<td>Intestinal dysbiosis in patients with primary sclerosing cholangitis...[4*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>263</td>
<td>Fecal microbial transplantation...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>264</td>
<td>What Causes Recurrence of Crohn's Disease...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>265</td>
<td>Enteric Microbiota Alterations in Patients...[6*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>266</td>
<td>Transmissive Crohn's disease-like ileitis...[2*][6]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>283</td>
<td>Deep remission in Crohn's disease...[1*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>284</td>
<td>Tuberculosis and Hepatitis B Reactivation...[7*][2]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>285</td>
<td>Inflammatory Bowel Disease Patients with Solid Organ...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>286</td>
<td>Drug concentrations and antibodies to infliximab...[5*] Prometheus laboratories performed the measurements of serum TNF and antibodies to infliximab in our samples. They were not involved in the processing and the statistical analysis of the results or the conclusions in this abstract.</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>287</td>
<td>Efficacy of adalimumab in patients...[3*] AbbVie</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>288</td>
<td>Anti-TNF withdrawal in IBD...[6*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>289</td>
<td>Genetic variability in SLCO2A1 and ABC4 genes...[4*][2]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>290</td>
<td>Relevance of DNA repair polymorphisms as genetic markers...[4*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>291</td>
<td>Mutations in DNA Polymerase Genes...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>292</td>
<td>Macrolide induced read-through of APC nonsense mutations...[6*][4]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>293</td>
<td>A novel &quot;Tumor in a Dish&quot; method to study...[4*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>294</td>
<td>Higher prevalence of cystic lesions of the pancreas...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>295</td>
<td>Pilot Study of the Safety, Feasibility, and Efficacy of...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>296</td>
<td>Effectiveness of Gastric Electrical Stimulation...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>297</td>
<td>Brainstem Dopamine Regulates Gastric Tone And Motility...[6*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>298</td>
<td>Altered Expression of Contractile Regulatory Proteins...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>299</td>
<td>Diabetic and Idiopathic Gastroparesis is Associated with...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>300</td>
<td>Oropharyngeal pH Testing is not Predictive...[4*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>301</td>
<td>The effect of esophageal acid exposure on esophageal reflexes...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>302</td>
<td>Esophageal Mucosal Impedance Pattern is Distinct...[3*] Funded by Sandhill Scientific, Inc.</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>303</td>
<td>Gastroesophageal reflux and esophageal motility...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>304</td>
<td>Utilization of surgical fundoplication in GERD patients...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>305</td>
<td>Novel mathematical algorithm with diagnostic...[2*][6]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>306</td>
<td>Impaired mucosal permeability underlies ongoing irritable bowel...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>307</td>
<td>Rifaximin for Prevention of NSAID-associated Intestinal Lesions...[3*] This study was supported by Alfa Wassermann SpA, Bologna, Italy.</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>308</td>
<td>The Incidence of Recurrent Diverticulitis...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>309</td>
<td>Epithelial Lesions In Environmental Enteropathy...[6*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>310</td>
<td>Bile Acid Diarrhea is associated with...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>311</td>
<td>Large Scale Validation of a Biomarker...[6*][3][2] Salix Pharmaceuticals, Inc.</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>312</td>
<td>Efficacy and Safety of ASP7147, a Bombesin-2 Receptor Antagonist ...[3*] Seldar Pharmaceuticals</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>313</td>
<td>Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain...[3*] Research funded by Salix Pharmaceuticals, Inc.</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>314</td>
<td>24 hour results from a placebo-controlled trial...[3*] ImHealthScience</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>315</td>
<td>Effect of Ramotseron in Female Patients...[3*][4]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>316</td>
<td>Eluxadoline Demonstrates Sustained Efficacy...[3*] Studies sponsored by Furiex Pharmaceuticals, a subsidiary of Actavis pk. Editorial support provided by Complete HealthVizion.</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>317</td>
<td>Results of a large RCT testing the effect of Cognitive Behavior Therapy...[2*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>318</td>
<td>Remission in Pediatric Inflammatory Bowel Disease...[5*]</td>
<td><em>(5</em>)</td>
</tr>
<tr>
<td>319</td>
<td>Analysis of rare variants identified by whole exome sequence...[2*]</td>
<td><em>(5</em>)</td>
</tr>
</tbody>
</table>

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>321</td>
<td>Vedolizumab Use in Pediatric Patients... (5)*</td>
</tr>
<tr>
<td>322</td>
<td>The Use of Vedolizumab for Treatment... (1)*</td>
</tr>
<tr>
<td>323</td>
<td>Steroids no more!... (5)*</td>
</tr>
<tr>
<td>324</td>
<td>Quantification of inflammation in small bowel Crohn's disease... (6)*</td>
</tr>
<tr>
<td>325</td>
<td>Abnormal regional homogeneity in patients... (2)*</td>
</tr>
<tr>
<td>326</td>
<td>Effects of CT Reconstruction Algorithm... (3)* Grant funding From Janssen Inc.</td>
</tr>
<tr>
<td>327</td>
<td>A randomized comparison of high definition colonoscopy... (4)*</td>
</tr>
<tr>
<td>328</td>
<td>The Usefulness of Ultra-low Dose CT colonography... (5)*</td>
</tr>
<tr>
<td>346</td>
<td>Engineering the Gut Microbiota to Treat Hyperammonemia... (2)*</td>
</tr>
<tr>
<td>347</td>
<td>Targeting a microRNA for the therapy... (4)*<a href="6">(2)</a>[(7)]</td>
</tr>
<tr>
<td>348</td>
<td>Clostridium difficile Toxin A Harbors Bacterial DNA... (6)*</td>
</tr>
<tr>
<td>349</td>
<td>Villus morphogenesis re-examined... (2)*</td>
</tr>
<tr>
<td>350</td>
<td>NGF promotes gastrointestinal cancer development... (2)*</td>
</tr>
<tr>
<td>351</td>
<td>Innate Immune IL1β Production is Critical... (2)*[(6)]</td>
</tr>
<tr>
<td>370</td>
<td>Effect of Azithromycin on esophageal hypomotility... (4)*</td>
</tr>
<tr>
<td>371</td>
<td>Low Esophageal Wall Blood Perfusion &amp; Hypoxia... (2)*</td>
</tr>
<tr>
<td>372</td>
<td>High Resolution esophageal manometry with a standardized test... (5)*</td>
</tr>
<tr>
<td>373</td>
<td>Pathophysiologic Correlates of Dysphagia in Patients... (2)*</td>
</tr>
<tr>
<td>374</td>
<td>Esophageal Contractions in Type 3 Achalasia... (2)*</td>
</tr>
<tr>
<td>375</td>
<td>Endogenous H2S contributes to myogenic tone generation... (5)*</td>
</tr>
<tr>
<td>376</td>
<td>Aspirin May Reduce the Risk of Gastric... (5)*</td>
</tr>
<tr>
<td>377</td>
<td>Discovery of Novel Gene-Fusions in Esophageal Adenocarcinoma... (2)*</td>
</tr>
<tr>
<td>378</td>
<td>Interleukin-17A promotes esophageal adenocarcinoma... (4)*</td>
</tr>
<tr>
<td>379</td>
<td>Expression of NOTCH signaling molecules... (2)*</td>
</tr>
<tr>
<td>380</td>
<td>Alcohol induces ALDH2 as a novel cytoprotective mechanism... (2)*</td>
</tr>
<tr>
<td>381</td>
<td>ALDH2 and autophagy may cooperate... (2)*[(3)] Raptor Pharmaceuticals</td>
</tr>
<tr>
<td>382</td>
<td>The Polycomb Histone Lysine Methyltransferase Ezh2... (2)*</td>
</tr>
<tr>
<td>383</td>
<td>Modulation of Ca2+ Waves in Human Enteric Glial Cells... (2)*[(4)]</td>
</tr>
<tr>
<td>384</td>
<td>Enteric glia are a transcriptionally distinct... (4)*<a href="2">(7)</a></td>
</tr>
<tr>
<td>385</td>
<td>Conditional Genomic Deletion of Ano1 in Kit-expressing Cells... (2)*</td>
</tr>
<tr>
<td>386</td>
<td>Endocannabinoid-mediated effects of substrate-selective COX-2... (2)*</td>
</tr>
<tr>
<td>387</td>
<td>Immunochip implicates multiple genetic loci... (2)*</td>
</tr>
<tr>
<td>388</td>
<td>Identifying genetically homogeneous Crohn’s disease... (2)*[(6)]</td>
</tr>
<tr>
<td>389</td>
<td>A candidate gene study of rare monogenic disorders... (4)*</td>
</tr>
<tr>
<td>390</td>
<td>Epigenetic and post-translational modification of STAT3... (2)*</td>
</tr>
<tr>
<td>391</td>
<td>A Crohn’s disease susceptibility gene A20... (4)*[(2)]</td>
</tr>
<tr>
<td>392</td>
<td>Short Bowel Syndrome: a case study... (2)*</td>
</tr>
<tr>
<td>393</td>
<td>Helicobacter pylori infection causes insulin resistance... (2)*</td>
</tr>
<tr>
<td>394</td>
<td>Epithelial Cell Heat Shock Protein 70 Expression... (4)*</td>
</tr>
<tr>
<td>395</td>
<td>Small Intestine Bacterial Overgrowth... (4)*</td>
</tr>
<tr>
<td>396</td>
<td>The effect of past antibiotic exposure on diabetes risk... (2)*</td>
</tr>
<tr>
<td>397</td>
<td>Colon Derived Propionate as Substrate for Gluconeogenesis... (4)*</td>
</tr>
<tr>
<td>398</td>
<td>Rifaximin displays a protective activity... (3)* Alfa Wassermann SpA, Bologna Italy</td>
</tr>
<tr>
<td>399</td>
<td>Down-regulation of peripheral myelin protein 22... (2)*</td>
</tr>
<tr>
<td>400</td>
<td>Krüppel-like factor 5 (KLFS) regulates... (2)*</td>
</tr>
<tr>
<td>401</td>
<td>Sirtuin-6 (Sirt6) is a critical protein... (2)*</td>
</tr>
<tr>
<td>402</td>
<td>Selective and reversible suppression of intestinal stem cell... (4)*</td>
</tr>
<tr>
<td>403</td>
<td>Tissue-specific induction of activating transcription factor 6... (2)*</td>
</tr>
<tr>
<td>404</td>
<td>ZBP-89 Recruits HDACs to β-Catenin Target Genes... (2)*</td>
</tr>
<tr>
<td>405</td>
<td>Cationic Amino Acid Transporter 2... (2)*</td>
</tr>
<tr>
<td>406</td>
<td>Milk fat globule-EGF factor 8 promotes colon cancer growth... (5)*</td>
</tr>
<tr>
<td>407</td>
<td>Blood vessel epicardial substance (BVES)-interacting protein... (2)*[(4)]</td>
</tr>
<tr>
<td>408</td>
<td>CD44 splicing and expression of CD44e splice variant... (2)*</td>
</tr>
<tr>
<td>409</td>
<td>Factors relating to GI bleeding induced by dual antiplatelet therapy... (5)*</td>
</tr>
<tr>
<td>410</td>
<td>Upper Gastrointestinal Mucosal Injury and Symptoms... (5)*</td>
</tr>
<tr>
<td>411</td>
<td>Can famotidine prevent recurrent peptic ulcer... (4)*</td>
</tr>
<tr>
<td>412</td>
<td>A Phase 3, Lansoprazole-controlled, Long-term Extension... (3)*</td>
</tr>
<tr>
<td>413</td>
<td>Comparison of in-hospital mortality... (5)*</td>
</tr>
<tr>
<td>414</td>
<td>Occult vs. Overt Upper Gastrointestinal Bleeding... (5)*</td>
</tr>
<tr>
<td>415</td>
<td>Small Bowel Dysmotility is Significantly Associated with... (5)*</td>
</tr>
<tr>
<td>416</td>
<td>Live But not Killed Sulfate-Reducing Bacteria... (6)*</td>
</tr>
<tr>
<td>417</td>
<td>Identification of Specific Bacteria in Jejunal Aspiration... (5)*</td>
</tr>
<tr>
<td>418</td>
<td>Quantifying the phase II motor patterns... (5)*</td>
</tr>
<tr>
<td>419</td>
<td>Gastrointestinal epithelia could be luminal sensors... (5)*</td>
</tr>
<tr>
<td>420</td>
<td>Quantitative analysis of Volumetric Laser Endomicroscopy... (3)* Ninepoint Medical</td>
</tr>
<tr>
<td>421</td>
<td>Development and validation of a NBI classification system... (5)*</td>
</tr>
<tr>
<td>Abstract Funding Source Key</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td>* = Primary Source</td>
<td></td>
</tr>
</tbody>
</table>

(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)

---

552. . . . . One Third Of Large Sessile Serrated Polyps...[5*]
553. . . . . Validation of NICE...[5*]
554. . . . . Diagnosis of sessile serrated adenomas/polyps...[5*]
555. . . . . Proteus trial: comparing neoplasia yield and attendance...[2*][3]
im3D S.P.A - Medical Imaging Lab, Torino, Italy
556. . . . . Accuracy and Inter-rater Reliability...[2*]
591a. . . . . The impact of organ failure on mortality in necrotizing pancreatitis...[5*]
591b. . . . . Natural History after Acute Necrotizing Pancreatitis...[5*]
591c. . . . . Primary Organ Failure and Secondary Organ Failure...[5*]
591d. . . . . Impact of up sizing percutaneous catheters...[5*]
591e. . . . . Significance of intra-abdominal pressure...[5*]
591f. . . . . Natural history of arterial pseudoaneurysms...[5*]
592. . . . . Histological Normalization is Associated with...[4*]
593. . . . . Predictive Value of Basal Plasmaocytosis...[4*]
594. . . . . Recurrence of Clostridium difficile infection...[4*]
595. . . . . Ustekinumab efficacy and safety in Crohn’s disease patients...[5*]
596. . . . . Clinical outcomes of inflammatory bowel disease...[2*]
597. . . . . Serological Antibodies for the Prediction...[5*]
598. . . . . Selective serotonin reuptake inhibitor...[2*][6]
599. . . . . Human pyloric sphincters bioengineered...[2*][4]
600. . . . . In situ implantation of autologous BioSphincter TM...[2*]
601. . . . . The appendix as a viable source of neural progenitor cells...[2*]
602. . . . . Cre/LoxP-mediated inducible activation of IKK2...[2*]
603. . . . . Helicobacter pylori activates gastric epithelial stem...[7*][2][4]
604. . . . . TFF1 tumor suppressor: a frontline key regulator...[2*]
605. . . . . The Ornithine Decarboxylase Inhibitor Difluoromethylornithine...[2*]
606. . . . . Nfkb1 deficiency alters susceptibility...[6*][4]
607. . . . . Toll-like receptor 10 in Helicobacter pylori infection...[2*]
608. . . . . Epidermal Growth Factor Receptor...[2*][4]
609. . . . . Increased expression of µ-opioid and cannabinoid receptors...[4*]
610. . . . . Elevated fecal bile acids are associated with abdominal pain...[2*][4]
611. . . . . Low-FODMAP diet in Irritable Bowel Syndrome patients...[6*][4]
612. . . . . characterization of intestinal microbiome...[2*][4]
613. . . . . Epithelial mesotrypsin in IBS: expression and function...[4*]
614. . . . . Effects of Fecal Microbial Transplantation...[4*][2]
615. . . . . Randomized, Double Blind Trial of Psyllium Fiber...[2*][6]
616. . . . . Reduced functional connections between the hypothalamus...[4*]
617. . . . . Efficient Gene Delivery to the Enteric Nervous System...[4*]
618. . . . . Effect of anesthesia in colon motility...[4*]
619. . . . . Single-electrode Colon Stimulation...[5*]
620. . . . . Nausea Complicating Recurrent Abdominal Pain...[2*][4]
631. . . . . The association between physician beliefs...[2*]
632. . . . . Electronic Medical Record Flags Have a Limited Impact...[4*]
633. . . . . Barriers to Patient Attendance...[5*]
634. . . . . Reducing First-Case Delays in a Large Academic Endoscopy Suite...[5*]
635. . . . . Implementing an Interdisciplinary Quality Initiative...[5*]
636. . . . . Quantity and Quality: Web-based reporting...[POSTER PRESENTATION][5*]
637. . . . . Quality Improvement in Bowel Preparation...[POSTER PRESENTATION][4*]
638. . . . . Split-dose polyethylene glycol (PEG) versus night-before...[POSTER PRESENTATION][No Funding Sources Provided]
639. . . . . Changes to adenoma detection rate...[POSTER PRESENTATION][No Funding Sources Provided]
640. . . . . Varying quality of dysplasia surveillance colonoscopies...[POSTER PRESENTATION][5*]
641. . . . . Patient Compliance: A Follow-up Phone...[POSTER PRESENTATION][No Funding Sources Provided]
642. . . . . Serrated Lesion Detection Rate...[POSTER PRESENTATION][5*]
643. . . . . Coordinating urgent endoscopy in an urban safety net...[POSTER PRESENTATION][5*]
644. . . . . Impact of Pre-Procedure Nursing Phone Calls...[POSTER PRESENTATION][5*]
645. . . . . Implementation of fecal immunochemical testing...[POSTER PRESENTATION][4*]
646. . . . . Duration of Surveillance for Gastroenteropancreatic...[5*]
647. . . . . Contrast Harmonic Endoscopic Ultrasonography...[5*]
648. . . . . Screening for Occult Tumor in Asymptomatic Members...[2*]
657. . . . . Risk and Protective Factors for Midgut Carcinoid Tumours...[4*]
668. . . . . Delays in Neuroendocrine Tumor (NET) Diagnosis...[3*] Funded by Novartis
drug. It does not impact the expression of short-chain fatty acid receptors...[4*]
The research is funded by TI Food and Nutrition, a public-private partnership on pre-competitive research in food and nutrition. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Microbiota adenomas improve the diagnostic yield.

Thromboembolism the Risk of Gastrointestinal Bleeding for upper gastrointestinal bleeding Associated with.

IGF-1 circadian rhythms protein kinase A.

Outcomes of Non-ulcer Bleeding Cancer.

Simulation and Sociodemographic Disparities productive academic.

(1) = Clinical Practice Funds     (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)     (3) = Industry or Commercial Entity     (4) = Institutional Funds     (5) = No Study Funding     (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)     (7) = Professional Organization (e.g. AGA, AASLD, etc.)
913. . . . . . Significant risk of post-colonoscopy colorectal cancer...{(5*)}

914. . . . . . Colon Carcinomas Arising from Sessile Serrated Polyps...{(2*)}

915. . . . . . Platelets Interact with Colorectal Cancer Cells...{(2*)}

916. . . . . . Is the McGill Pain Questionnaire useful...{(2*)}[[3]]{(6) AbbVie

917. . . . . . A meta-analysis and systematic review...{(5*)}

918. . . . . . Low levels of Pancreatic Elastase-1...{(5*)}

919. . . . . . Circulating Micro RNA 375 Levels Inversely Correlated...{(4*)}

920. . . . . . Chronic Gastrointestinal Dysmotility and its Effect...{(5*)}

921. . . . . . Small Intestinal Bacterial Overgrowth...{(5*)}

922. . . . . . Comparative Effectiveness and Safety of Anti-TNF Agents...{(7*)}

923. . . . . . Comparative Effectiveness and Safety of Infliximab...{(7*)}

924. . . . . . Long-term outcomes of top-down versus step-up ...{(5*)}

925. . . . . . Comparing Long Term Outcomes Between Infliximab And Adalimumab...{(6*)}

926. . . . . . Specific antibody response to two Pneumococcal Vaccines...{(3*)}[(1) Pfizer

927. . . . . . End to end vs side to side anastomosis and post-operative...{(2*)}

928. . . . . . Double blind randomised controlled trial...{(2*)}

929. . . . . . Age Related External Anal Sphincter Muscle...{(2*)}

930. . . . . . Is Rectal Hypersensitivity caused by bidirectional gut...{(2*)}

931. . . . . . A glove-based, disposable, point-of-service device...{(4*)}

932. . . . . . Resting anal pressure, not outlet obstruction...{(5*)}

933. . . . . . A prospective randomized study comparing conventional ESD...{(5*)}

934. . . . . . Endoscopic sleeve gastropasty...{(3*)} Apollo Endosurgery

935. . . . . . A Novel EUS-guided Liver Biopsy Needle...{(5*)}

936. . . . . . Detection of infection in fluid collections...{(5*)}

937. . . . . . Analytic morphomics accurately identifies...{(7*)}

938. . . . . . Muscle atrophy in patients with chronic hepatitis...{(5*)}

939. . . . . . Visceral anatomy correlates with increased risk...{(7*)}

940. . . . . . miRNA and mRNA profiles from nondysplastic mucosa...{(2*)}[(6)

941. . . . . . Expression of Csk is associated with its methylation status...{(4*)}

942. . . . . . Racial/ethnic groupings influence...{(2*)}[(7]

943. . . . . . Promoter hypermethylation of a Novel Tumor Suppressor Gene...{(2*)}

944. . . . . . Systematic, Robust, Reversible DNA...{(2*)}

945. . . . . . Infection of H. pylori is associated with...{(7*)}

946. . . . . . Do all low-risk colorectal adenomas predict equal risk...{(2*)}

947. . . . . . Outreach invitations for FIT and colonoscopy improve...{(2*)}

948. . . . . . Where does the Pharmaceutical Industry spend its money...{(5*)}

949. . . . . . An electronic medical record-based workflow...{(5*)}

950. . . . . . Addressing Unmet Needs of Inflammatory Bowel Disease...{(2*)}[(6) NIH K23 DK097451-02 CCFA Ref # 253624

951. . . . . . Biophotonic Detection of High Order Chromatin Alterations...{(4*)}

952. . . . . . Age-Specific Disparities in Hepatocellular Carcinoma...{(5*)}

953. . . . . . Race/Ethnicity-Specific Disparities...{(5*)}

954. . . . . . Proposal of a new staging system for ampulla of Vater cancer...{(5*)}

955. . . . . . Volatile organic compounds in Urine...{(2*)}

956. . . . . . IW-9179, a potent guanylate cyclase-C (GC-C) agonist...{(3*)} Ironwood Pharmaceuticals, Inc.

957. . . . . . Human Derived Gut Microbiota Influence...{(2*)}[(4]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NHI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
1026. Changes of the colonic wall structure disease...[1*]

1027. Ulcerative colitis patients in clinical remission...[5*]

1028. Chronic activation of the GC-C/cGMP pathway...[3*] Forest Laboratories, Inc., a subsidiary of Actavis plc, and Ironwood Pharmaceuticals, Inc., were involved in the study design; collection, analysis and data interpretation; and decision to submit these data for presentation. Studies were sponsored by Forest Laboratories, Inc., a subsidiary of Actavis plc, Ironwood Pharmaceuticals, Inc., and NHMRC Australia.

1029. Visceral Hypersensitivity is an Important Etiological Factor...[2*]

1030. TRPM8 Function and Expression...[2*]

1031. Role of Sex Hormones and Sex Chromosomes...[2*]

1032. Development of a novel preparation...[2*]

1033. Prevalent and Incident Lesions Identified with Pancreatic Cancer...[5*]

1034. Spectral Biomarkers of Pancreatic Cancer...[2*][4]

1035. Risk for developing adverse outcomes...[5*]

1037. Serum human telomerase reverse...[5*]

1045. Arabinoxylans show distinct prebiotic properties...[3*] BioActor B.V., Maastricht, The Netherlands

1046. A diet rich in arabinoseylan and resistant starch...[2*] Lantmännen provided rye flakes, wheat bran, rye bread and specially designed fiber rich products, KMCamba (Brande, Denmark) provided raw potato starch, DuPont Nutrition and Biosciences ApS (Brabrand, Denmark) provided enzymatically treated wheat bran; and Ingredion Incorporated (Bridgewater, NJ, USA) provided Hi-maize for the interventions.

1047. A probiotic-derived protein stimulates IgA production...[2*][4]

1048. Selected non-digestible polysaccharides...[2*]

1049. Mucosal adhesion and anti-inflammatory effect...[4*]

1050. The prebiotic inulin enhances fat oxidation...[4*] The research is funded by TI Food and Nutrition, a public-private partnership on pre-competitive research in food and nutrition. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NHI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
AGA Poster Presentations
<table>
<thead>
<tr>
<th>Abstract Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>* = Primary Source</td>
</tr>
</tbody>
</table>

(1) = Clinical Practice Funds     (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)     (3) = Industry or Commercial Entity     (4) = Institutional Funds     (5) = No Study Funding     (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)     (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Pylopric deformity

The Cardia

Endoscopic Mucosal Resection

Symptom of abdomen from oral mucosal ampullary duodenal adenomas

Esophageal dilation and image quality factors for GI imaging

Transit Time

Highly Selective Targeted Balloon or bougienage for Survival analysis of early Pretreatment antral or Smoking, a previous history of Intestinal Metaplasia (IM) of

Potential role of volumetric laser endomicroscopy

Three-dimensional myoarchitecture of porcine

Randomized Controlled Trial of Self-Directed vs. In-classroom

Early improvement of liver stiffness

Sensitivity of pretargeted 68Ga PET-CT

Utility of transient elastography

Extracolonic neoplasias in Inflammatory Bowel Disease

Withdrawning or continuing maintenance treatment

Clinical features of active tuberculosis

The Effect of Anti-Drug Antibodies on Adverse Events

Diabetes is an independent risk factor

Impact of Infliximab on Short-term Postoperative Outcomes

Infusion-related reactions with vedolizumab. The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co).

Does folate supplementation reduce colorectal cancer

Anti-TNF agents may pose a higher risk of infection

Efficacy, toxicity and positive psychological effects

Cutaneous events during anti-tumour necrosis

Incident Infectious and Malignant Adverse Event Risk

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds

(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1149. . . . Stability of serological markers and their predictive value...(5*)
Serological testing was performed by Prometheus laboratories.

Sa1150. . . . Early initiation of adalimumab significantly diminishes...(3*)
An investigator initiated study (IIS) funded by AbbVie.

Sa1151. . . . Intestinal transplantation for Crohn’s disease...(5*)

Sa1152. . . . Do Anti-TNF Agents Work...(5*)

Sa1153. . . . Inflammatory bowel disease and Pregnancy Outcomes...(2*)

Sa1154. . . . Plexitis as a predictive factor for early post-operative...(5*)

Sa1155. . . . Smoking is associated with higher healthcare...(3*)
Unrestricted grant from AbbVie.

Sa1156. . . . Accelerated treatment strategy in inflammatory bowel...(5*)

Sa1157. . . . Presence of anaemia is an indicator...(5*)

Sa1158. . . . A single factor of compliance may not be sufficient...(3*)
Ferring Arzneimittel GmbH.

Sa1159. . . . Infection-related Hospitalizations in Patients...(6*)

Sa1160. . . . Mucosal healing in ulcerative colitis...(5*)

Sa1161. . . . Predictors of post-operative endoscopic recurrence...(6*)
(3) Financial support from MSD

Sa1162. . . . Systematic evaluation of clinical predictors...(2*)

Sa1163. . . . Treatment for Clostridium Difficile Infection...(5*)

Sa1164. . . . Do Sporadic Adenomas Behave Differently...(5*)

Sa1165. . . . Improving outcomes in patients...(4*)

Sa1166. . . . Predictors, and a simple severity risk scoring system...(5*)

Sa1167. . . . Altered bowel pattern in IBD in remission...(6*)
(4)

Sa1168. . . . Are extraintestinal manifestations associated with...Crohn’s disease?...(5*)

Sa1169. . . . Are extraintestinal manifestations associated with...ulcerative colitis?...(5*)

Sa1170. . . . Inflammatory Bowel Disease in the Elderly...(1*)

Sa1171. . . . Diagnostic delay is associated with...(5*)

Sa1172. . . . Role of social and psychological factors...(6*)

Sa1173. . . . The T300A variant of ATG16L1 affects clinical course...(2*)

Sa1174. . . . The impact of magnetic resonance enterography...(6*)
The study was sponsored by the Helmsley Charitable Trust.

Sa1175. . . . Clinical outcomes of surgery versus endoscopic...(5*)

Sa1176. . . . Incidence and associated factors of cutaneous...(5*)

Sa1177. . . . Ulcerative colitis patients undergoing pouch surgery...(4*)
(6) The Leona M. and Harry B. Helmsley charitable trust.

Sa1178. . . . Concomitant use of enteral nutrition therapy...(5*)

Sa1179. . . . Higher 25-hydroxyvitamin D levels are associated...(3*)
Takeda Pharmaceuticals, America, Inc.

Sa1180. . . . Effect of Immunosuppressive Therapies for the Treatment...(5*)

Sa1181. . . . Upper gastrointestinal Crohn’s Disease...(5*)

Sa1182. . . . Single-Center Experience of Vedolizumab...(5*)

Sa1183. . . . Adverse Events to Thiopurines Can Be Overcome...(4*)

Sa1184. . . . The role of faecal S100A12...(6*)

Sa1185. . . . Safety and long term outcome of primary...(5*)

Sa1186. . . . Prognostic Significance of Anti-Saccaromyces...(5*)

Sa1187. . . . Peripheral blood eosinophilia in patients...(2*)

Sa1188. . . . Momentary ratings versus recalled ratings...(2*)

Sa1189. . . . Colonic Neoplasia in IBD and Non-IBD...(2*)

Sa1190. . . . Early Remission Status as a Predictor...(3*)
UCB Pharma

Sa1191. . . . Excessive Gain in Visceral Adipose Tissue...(5*)

Sa1192. . . . Predictors of Indeterminate QuantiFERON-TB Gold Testing...(5*)

Sa1193. . . . Ulcerative Proctitis: Predictors and outcomes...(5*)

Sa1194. . . . Consistently High C Reactive Protein is Associated with...(4*)
(2)

Sa1195. . . . The efficacy of azathioprine and tumour necrosis...(5*)

Sa1196. . . . Disease Duration and Narcotics are Associated with...(5*)

Sa1197. . . . Factors Associated with Treatment Outcome...(5*)

Sa1198. . . . Initial Vedolizumab Cohort...(3*)
Takeda Pharmaceutical Company

Sa1199. . . . Inflammatory bowel disease flares associated with...(5*)

Sa1200. . . . Predictors Of 3-Year Risk Of Colectomy...(5*)

Sa1201. . . . Infliximab salvage outcomes...(4*)

Sa1202. . . . Recurrence Rate and Risk Factors...(5*)

Sa1203. . . . Appendiceal orifice histology and its prognostic significance...(5*)

Sa1204. . . . Deep remission as a predictor...(3*)
The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Sa1205. . . . The Impact of Health Literacy...(6*)

Sa1206. . . . Long-term safety and efficacy of accelerated infliximab infusions...(5*)

Sa1207. . . . Endoscopic Examination Is Necessary...(5*)

Sa1208. . . . Granulomas in mesenteric lymph nodes...(5*)

Sa1209. . . . Comparable outcome of consistent versus switched anti-TNF...(5*)

Sa1210. . . . Perioperative blood transfusion...(5*)

---

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
The characteristics and clinical outcomes... (5*)

IBD Patients Are Frequently Non-Adherent... (4*) Alberta IBD Consortium Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) University of Alberta Hospital Foundation Kimberley Homes IBD Fund

An analysis of Crohn’s Disease over the past decade... (5*)

Ulcerative Colitis trends in costs of hospitalization... (5*)

Differences In Healthcare Expenditures In Crohn’s... (2*) Janssen Services, LLC. Mean SIBDQ to stratify Crohn’s disease patients: Impact of neuropsychiatric illness, chronic pain and refractory inflammation.

Management differences between early and late-onset... (5*)

A protocol to avoid corticosteroid exposure... (5*)

The outcome of 142 endoscopic balloon dilatations... (5*)

Remission Rates In Crohn’s Disease Patients... (3*) UCBR Pharma

Stopping Infliximab during Pregnancy... (5*)

Predictors of Readmissions in Hospitalized Patients... (5*)

Impact of adenomatous colon polyps... (5*)

Scheduled sequential therapy based on fecal microbiota... (2*) (4)

Nonbloody Diarrhea but Not Significant Weight Loss... (5*)

Risk of relapse after anti-TNF discontinuation... (5*)

Predictors of early and late unplanned re-admissions... (5*)

Long term outcomes of Crohn’s anastomotic strictures... (5*)

Predictors of Relapse Following Withdrawal... (5*)

Durable Clinical Remission and Response... (3*) AbbVie funded the research and provided writing support.

Body Mass Index, Genetic Susceptibility... (2*)

Oral Contraceptive Use and Risk... (2*)

Efficacy & safety of azathioprine... (5*)

Early diagnosis of Crohn’s Disease... (5*)

The Introduction of Anti-TNF Therapy... (1*) (4)

The influence of disease activity... (5*)

Meta-Regression of Mucosal Healing... (5*)

Long-Term Evaluation of Preoperative Wireless... (5*)

Direct and indirect effects of tofacitinib... (3*) Pfizer Inc.

Does failure to respond to one anti-TNF agent... (5*)

Clinical utility of the Lémann index... (5*)

The prognosis of ulcerative colitis patients... (4*)

Clinical outcomes of ileocecal Crohn’s disease... (5*)

Defensins Alpha 5 and 6 are Up-regulated... (4*)

CD24 Polymorphisms: Potential contribution... (4*)

A Comparison of Combination Therapy... (3*) Takeda Pharmaceuticals, America, Inc.

Long term assessment of clinical response... (5*)

Risk Factors For Re-hospitalization... (5*)

Comparison between Sci-B-VacTM... (4*)

Azathioprine and 6-mercaptopurine are equally effective... (2*)

Inhibition of plasmin protects against experimental... (5*)

Ultrasound-Mediated Gastrointestinal Drug Delivery... (2*)

Systematic Review and Meta-Analysis... (5*)

Abstract Funding Source Key

*= Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NNI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CICA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Comparison of Real-World Outcomes of Adalimumab... (3*) Financial support for the study and medical writing support (Tonya Goodman, Arbor Communications, Ann Arbor, MI) was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content.

The impact of hormonal contraceptives... (4*) (2)

Durability of the anti-HBs titers... (5*)

Vedolizumab for the Treatment of Fistulizing Crohn’s Disease... (3*) The clinical study was funded by Milleium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Patient-Reported Outcomes with GED-0301... (3*) Celgene Corporation

A Prospective Multicenter Trial Evaluating... (3*) UCB

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group... (3*) GW Research Ltd

Adalimumab Serum Concentration... (3*) AbbVie

Interferon-γ Release Assay Versus Tuberculin Skin Test... (3*) PURSUIT studies supported by Janssen Research & Development, LLC.

Prospective, randomized clinical trial... (5*)

Individualized therapy is long-term cost-effective... (6*)

Adjuvant Allopurinol in Azathioprine/6-mercaptopurine... (6*) (4)
Sa1270. Efficacy of vedolizumab...Crohn’s disease... The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Sa1271. Efficacy of vedolizumab...ulcerative colitis... The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Sa1272. Efficacy and safety of retreatment...ulcerative colitis... The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Sa1273. Efficacy and safety of retreatment...Crohn’s disease... The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Sa1274. Efficacy and safety of vedolizumab...(3*) The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Sa1275. The Diagnostic Delay in Celiac Disease...(5*)

Sa1276. The Perspective of Celiac Disease Patients...(5*)

Sa1277. Functional gastrointestinal symptoms in patients...(2*)

Sa1278. Assessing the Genetic Susceptibility for Celiac Disease...(5*)

Sa1279. Short-Term Progression of Histology... (5*)

Sa1280. The Gluten-Free Diet Alone...(3*) Alvine Pharmaceuticals, Inc.

Sa1281. Long-term outcome of a series of patients...(5*)

Sa1282. Attitudes toward genetic testing...(5*)

Sa1283. Prevalence of Comorbidities in Patients...(3*) Design, conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content. Medical writing support was provided by Cathryn M. Carter, MS, of Arbor Communications, Inc.; this support was funded by AbbVie.

Sa1284. Effects of adherence to gluten-free diet...(5*)

Sa1285. Candidates for Celiac Disease Diagnosis Go Untested...(5*)

Sa1286. Vaccination Outcomes in Celiac Disease...(5*)

Sa1287. Comparison Between Anti-Transglutaminase Serum...(5*)

Sa1288. Pancreatic Exocrine Insufficiency in Adult...(5*)

Sa1289. Isolated elevation of DGP IgA antibodies...(5*)

Sa1290. Risk of celiac disease in the first and second degree...(5*)

Sa1291. Clinical Characteristics, Associated Conditions...(5*)

Sa1292. Concomitant Celiac Disease Does Not Modify...(5*)

Sa1293. Endoscopic appearance correlates poorly...(5*)

Sa1294. Lymphocytic Gastritis in Patients...(5*)

Sa1295. Reflux symptoms in patients...(5*)

Sa1296. Duodenal Eosinophilia in Celiac Disease...(2*)

Sa1297. The Degree of Mucosal Damage...(5*)

Sa1298. Perceived wellbeing in celiac disease...(5*)

Sa1299. Raised Intraepithelial Lymphocytes in the Presence...(5*)

Sa1300. An Opportunity Missed in Diagnosing...(5*)

Sa1301. High Rates of Prior Celiac Disease...(5*)

Sa1302. Delay in diagnosis of celiac disease...(5*)

Sa1303. The gluten-free diet produces...(5*)

Sa1304. Bone Mineral density in Celiac Disease...(5*)

Sa1305. Point of Care testing for Adult Coeliac Disease...(3*) Tillotts Pharma

Sa1306. Point of care testing for celiac disease...(3*) Tillotts Pharma

Sa1307. Comparison of three commercially available...(3*) BHR Pharmaceuticals; Tillotts Pharma

Sa1308. Predicting histological remission in patients...(3*) Tillotts Pharma

Sa1309. Natural history and follow-up of non-celiac...(5*)

Sa1310. Is the response to Hepatitis B vaccine...(5*)

Sa1311. Early recognition of possible pitfalls...(5*)

Sa1312. Preoperative scoring system to predict...(5*)

Sa1313. A significant proportion of patients with cholelithiasis...(5*)

Sa1314. Effects of Early Biliary Drainage...(4*)

Sa1315. Appropriate Empiric Antibiotic Therapy...(5*)

Sa1316. Long term results of Endoscopic Radiologic...(5*)

Sa1317. Magnetic resonance cholangio-pancreatography...(5*)

Sa1318. Long-term outcomes in patients with gallstones...(5*)

Sa1319. Natural History of Gallbladder Polyps...(5*)

Sa1320. Eicosapentaenoic acid dissolves cholesterol gallstones...(4*)

Sa1321. Mid-term Results of Recanalization...(4*)

Sa1322. Impact of Concurrent non-IBD Immunological Diseases...(5*)

Sa1323. Speed is Life: Delay in appropriate antimicrobial...(5*)

Sa1324. Effects of Vorinostat-Incorporated Nanoparticles...(5*)

Sa1325. Is There Any Difference in Causative Pathogen...(5*)

Sa1326. Merits and demerits of steroid therapy...(5*)

Sa1327. Analysis of Discrepancy in Radiologic...(5*)

Sa1328. Analysis of the human biliary microbiome...(5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1329..... Serum complement C5a level correlates...[5*]
Sa1330..... Small Vessel Hepatic Arteriopathy...[5*]
Sa1331..... Risk Factors for Gallstone Formation...[5*]
Sa1332..... Ghrelin is elevated in patients...[1*]
Sa1333..... Risk Factors for In-hospital Mortality...[5*]
Sa1334..... Effect of minor endoscopic sphincterotomy...[5*]
Sa1335..... Inpatient burden of Cholangitis in the United States...[5*]
Sa1336..... Molecular mechanisms underlying the critical role...[2*]
Sa1337..... Treatment with Milk Thistle, Ursodeoxycholic Acid...[5*]
Sa1338..... Concordance of Presenting Symptoms...[5*]
Sa1339..... Lessons learned from 120 consecutives...[5*]
Sa1340..... Comparison of Anorectal Manometry...[2*][3] Covidien GI Solutions (formerly Given Imaging) provided prototype probe holders for this study.
Sa1341..... Reproducibility of High Resolution (2D)...[2*]
Sa1342..... Endorectal Balloon (ERB) During Image Guided...[4*][6]
Sa1343..... Efficacy of anorectal biofeedback...[5*]
Sa1344..... Anal function after Transanal Endoscopic Microsurgery...[5*]
Sa1345..... Fecal Incontinence Severity Index Helps...[3*][2] Salix Pharmaceuticals
Sa1346..... What Makes Discussing Fecal Incontinence...[2*][3] Supported by Salix Pharmaceuticals and AHRQ grant R01 HS018695
Sa1347..... Identification of overlapping dysynergic defecation...[4*]
Sa1348..... A Novel High-resolution Anorectal Squeezing Parameter...[5*]
Sa1349..... Bimodal Effect of Oxidative Stress...[2*]
Sa1350..... Magnetic Resonance Diffusion Tensor Imaging...[2*]
Sa1351..... Biofeedback for faecal incontinence in men...[5*]
Sa1352..... Biofeedback for constipation and faecal incontinence...[5*]
Sa1353..... Assessment of pelvic floor dyssynergia...[4*]
Sa1354..... Comparison between defecography and echodendrography...[4*]
Sa1355..... Assessment of Pathophysiology of Patients...[4*]
Sa1356..... Micro CT and Histology Evidence...[2*]
Sa1357..... External Anal Sphincter Dysfunction...[2*]
Sa1358..... Men Report More Severe Fecal Incontinence...[3*][2] Supported by Salix Pharmaceuticals and AHRQ grant R01 HS018695.
Sa1359..... Novel Insights into the Mechanisms...[2*] Covidien GI solutions (formerly Given Imaging) provided the anorectal probe holders and video-ARM synchronizing equipment for the study.
Sa1360..... Canal anal pressure profile at rest...[3*] This study was funded with a research grant from Given Imaging.
Sa1361..... Nature of Extracellular Signal...[2*]
Sa1362..... Rectal hyposensitivity and slow colonic transit...[5*]
Sa1363..... International survey of methods...[5*]
Sa1364..... Prospective comparison of test performance...[1*]
Sa1365..... Successful Implantation of a Tissue Engineered Gut...[2*][4] Salix Pharmaceuticals
Sa1366..... Fecal Incontinence is Associated with...[2*][3] Supported by Salix Pharmaceuticals and AHRQ grant R01 HS018695.
Sa1368..... The value of a balloon expulsion test...[5*]
Sa1369..... A repeated anorectal manometry...[5*]
Sa1370..... Utility of MRI Defecography...[5*]
Sa1371..... Diabetic constipation patients...[5*]
Sa1372..... Can 3D High Resolution Anorectal Manometry Detect...[5*]
Sa1373..... Significant Findings from a Randomised Control trial...[7*]
Sa1374..... Assessment of Sexual Function In Relation to...[5*]
Sa1375..... Medical Management of Constipation...[5*]
Sa1376..... Effect of linaclotide on colonic motility...[4*]
Sa1377..... Preserved colonic meal response and functional evidence...[2*]
Sa1378..... Reduction of breath methane using rifaximin...[4*]
Sa1379..... VIP Expression in the Submucosal Plexus...[4*]
Sa1380..... A Novel Approach to Identify Genes...[6*]
Sa1381..... The effect of Chang Run Tong...[5*]
Sa1382..... Gastrointestinal Problems Associated with Multiple Sclerosis...[5*]
Sa1383..... Efficacy of multidisciplinary approach...[5*]
Sa1384..... Clinical Features and Colonic Motor Disturbances...[5*]
Sa1387..... Long-term follow-up of a prospective, open, multicenter...[3*] Medtronic
Sa1388..... Predictive capability of ultrasonographic evaluation...[4*]
Sa1389..... The safety, tolerability, and pharmacokinetics...[3*] Dong-A ST Co., Ltd.
Sa1390..... Efficacy and safety of prucalopride...[3*] This study was funded by Shire.
Sa1391..... Shy Bowel disorder may be an under-recognized...[5*]
Sa1392..... The use of pictograms to identify postures...[5*]

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CFTA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1393. Oral Treatment with SP-333. This study was funded by a grant from Synergy Pharmaceuticals, Inc.


Sa1395. Recto-sigmoid localization of radiopaque markers. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1396. Effects of RQ-00000010, the novel 5-HT4 receptor. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1397. Effect of linaclotide on patient-reported confidence. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1398. Treatment With Naloxegol Versus Placebo. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1721. Dedifferentiation/metaplasia of gastric chief cells. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1722. Actions of Nitric Oxide (NO) or Hydrogen Sulfide. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1723. Vasoactive mediators carbon monoxide. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1724. Effect of the new oral anticoagulant dabigatran. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1725. FFA2 activation suppresses basal. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1726. Different roles for various subtypes of K+ channels. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.


Sa1728. Chronic alcohol abuse induces Paneth cell... Wissenschaftsförderung der deutschen Brauwirtschaft (Science sponsorship by the German brewing industry).

Sa1729. Expression of epidermal growth factor receptor... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1730. Several active ingredients synergistically contribute... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1731. Proton pump inhibitor and Clopidogrel Interactions. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1732. Efficacy of oral Budesonide... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1733. NSAID-Induced Lower Gut Injury... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1734. Evaluation of a novel full covered biodegradable... Health Ministry Micro-tech limited.

Sa1735. Regular Swimming Exercise Ameliorates... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1736. Esophageal muscularis mucosa contraction... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1737. SLC01B1 genotype as a risk marker... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1738. hepatocellular growth factor increases esophageal epithelium... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1739. A total of 379 multiple white and flat elevated lesions... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1740. Upper Gastrointestinal Mucosal Injury... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1741. The antrum and corpus mRNA and small-RNA profile... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1742. Pre-Pylorus Pseudomelanosis... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1743. Caustic injury of the esophagus... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1744. Indomethacin-induced injury in the gastrointestinal... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1745. Gastric mucormycosis: a devastating fungal infection... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1746. Comparison of mucosal damage... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1747. Alkaline Injuries: How Far Down... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1748. Pediatric Case of Emphysematous Gastritis... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1749. Serological Diagnosis of Upper GI Diseases... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1750. Gastric Aggressive Factors... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1751. Interleukin-6 drives production... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1752. The role of Th17 cell plasticity... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1753. Altered NK cell homeostasis, NK immune-modulation... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1754. Distinctive Th17 lymphocyte plasticity... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1755. Peripheral blood E.coli Outer Membrane... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1756. The renin-angiotensin system promotes colitis... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1757. Targeting innate immune receptors... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1758. In vitro adalimumab exposure decreases R00yt... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1759. CD39 expression by CD8+ T cells... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1760. MiR-155 is crucial for Th17 cell development... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1761. Anti-TNF therapy switches on CD39+ FoxP3 Tregs... AbbVie sponsorship of 2 year MD.

Sa1762. Epithelial netrin-1 controls CD4 Th1 T-Cell... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1763. 1,25-Dihydroxyvitamin D3 Decreases Th1 and Th1 Lymphocyes... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1764. Poly(ADP-ribose) polymerase 1 (PARP1) expression... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1765. Role of Poly(ADP-ribose) polymerase 1 (PARP1)... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1766. Metformin induces mir-10b expression... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1767. Alkylresorcinols, Indicator for Gluten Consumption... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1768. In the Intestinal Mucosa of Children... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1769. Glutatin peptide P31-43 and viral ligand loxoribine... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1770. Structural and functional changes... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1771. Lack of Thymic Stromal Lymphopoietin Down-Regulation... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1772. ILC-like lymphomas in refractory celiac disease... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1773. Reduced T-Cell receptor variability... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Sa1774. Does the Donor Matter?... Rebiotix Inc., Roseville, MN.

Sa1775. Salmonella Typhimurium infection... AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.

Abstract Funding Source Key
* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Sa1948. . . . . Multiplex Helicobacter pylori Serology and risk...(2*)
Sa1949. . . . . Methylated BCAT1 and IKZF1 DNA in plasma...(4*) (3) Clinical Genomics
Sa1950. . . . . Derlin-1 is Overexpressed in Human Colorectal Cancer...(5*)
Sa1951. . . . . Circulating microRNA-203 predicts metastases...(2*)
Sa1952. . . . . Unraveling the Mechanisms Involved in Exercise Prevention...(4*)
Sa1953. . . . . Epigallocatechin-3-gallate (EGCG) targets cancer...(2*)
Sa1954. . . . . Vitamin D deficiency promotes hepatocellular cancer...(2*) (4*)
Sa1955. . . . . Vitamin D Supplementation Inhibits Colon Cancer...(7*) Supported by a grant from the Dairy Farmers of Canada.
Sa1956. . . . . Multiple dosing regimen with (-)-epigallocatechin-gallate...(4*)
Sa1957. . . . . Nano-Curcumin inhibits neoplastic process...(4*)
Sa1958. . . . . Statin Use May Decrease the Risk of Esophageal Adenocarcinoma...(2*)
Sa1959. . . . . Angiogenesis occurs very early...(2*)
Sa1960. . . . . Novel Epigenetic: Metabolic Axis in Early Colon...(7*)
Sa1961. . . . . Advanced synchronous adenoma predicts metachronous...(5*)
Sa1962. . . . . Surgical resection for T1 colorectal carcinoma...(5*)
Sa1963. . . . . Identification of individuals at risk for gastric cancer...(5*)
Sa1964. . . . . clinical risk assessment for gastric cancer...(5*)
Sa1965. . . . . Poor oral hygiene is associated with...(2*)
Sa1966. . . . . Metformin Modulates Tumor Growth...(4*)
Sa1967. . . . . The Effect of Flavonoids Luteolin and Quercetin...(4*) (2)
Sa1968. . . . . The association of patients perception...(5*)
Sa1969. . . . . Suppressive effects of irsagludine...(2*)
Sa1970. . . . . Colorectal cancer prevention in an animal...(2*)
Sa1971. . . . . Low-dose Acetylsalicylic Acid and Risk of Colorectal Cancer...(3*) Bayer Pharma AG
Sa1972. . . . . Berberine may rescue Fusobacterium nucleatum-induced...(2*) (4) This work was supported by grants from the National Natural Science Foundation (Grant No. 81320108024 and 81421001) to FYI: The Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 201268) to HJ.
Sa1973. . . . . Analysis and clinical evaluation of Kalikrein-related peptidase 5...(4*)
Sa1974. . . . . Long-term Exposure To Low Concentration Of Radioactive...(2*)
Sa1975. . . . . A Prospective Study of Regular Aspirin Use...(2*)
Sa1976. . . . . Silencing Lgr5 Inhibit the Metastasis...(5*)
Sa1977. . . . . Kynurenine metabolic pathway as a rational target...(2*)
Sa1978. . . . . Overexpression of Her2 converted the KRAS-driven...(2*)
Sa1979. . . . . The Role of piRNA-823 in Human Colorectal Cancer...(5*)
Sa1980. . . . . EGFR inhibition promotes differentiation...(2*)
Sa1981. . . . . Snail-mediated miR-133b functions...(2*) (4)
Sa1982. . . . . ROCK1-mediated EZH2 overexpression...(5*)
Sa1983. . . . . long non-coding RNA MALAT-1 promote...(2*)
Sa1984. . . . . Helicobacter pylori-related Long Noncoding RNA...(2*)
Sa1985. . . . . The role of HOXB7 in gastric carcinogenesis...(7*)
Sa1986. . . . . Clinopathologic characteristics...(5*)
Sa1987. . . . . Lipid phosphatase SHIP2 functions...(6*)
Sa1988. . . . . An anti-tumorigenic role for the IL-33/ST2 axis...(2*)
Sa1989. . . . . Cellular energy metabolism in the colorectal...(4*) (2)
Sa1990. . . . . Frequent Allelic loss of HIF3A Region in Liver Metastasis...(2*) (4)
Sa1991. . . . . Metastasis Candidate Genes on 9p24.2...(2*) (4)
Sa1992. . . . . Interplay between butyrate...(2*) (4)
Sa1993. . . . . Specific inhibitor of importin-a mediated nuclear transport...(4*)
Sa1993a. . . . . Reduced expression of prostaglandin transporter...(5*)
Sa1994. . . . . Long-term outcome of children born to IBD mothers...(4*) We received a fund from ZonMw. This is a Dutch organisation that funds health research. ZonMw’s main commissioning organisation is the Ministry of Health, Welfare and Sport and the Netherlands.
Sa1995. . . . . The prevalence of irritable bowel syndrome-like...(5*)
Sa1996. . . . . Increased Risk of Varicella-and Zoster-related Hospitalizations...(5*)
Sa1997. . . . . Identifying Fistulizing Crohn’s Disease...(4*)
Sa1998. . . . . “But I’m feeling fine!”...(4*)
Sa1999. . . . . Patient Related Outcomes and Disease Activity...(2*)
Sa2000. . . . . Cumulative steroid usage is not associated with permanent growth...(6*)
Sa2001. . . . . Differences in Emergency Department Evaluation...(6*)
Sa2003. . . . . Clostridium difficile Infection in Pediatric Inflammatory Bowel...(5*)
Sa2004. . . . . Transition Care in Inflammatory Bowel Disease...(5*)
Sa2005. . . . . Vasculitic skin rash as initial presentation...(5*)
Sa2006. . . . . DNA methylation in the intestine and peripheral blood...(7*) This study is funded by the CCFC (Crohn’s and colitis foundation of Canada).
Sa2007. . . . . New variant in MYO5B gene...(5*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)


Sa2008. . . . Peripheral hyperglycemia activates GABAergic...[(2*)]
Sa2009. . . . Gastrointestinal patients’ psychopathological level....[(6*)][(4*)]
Sa2010. . . . The endogenous cholinergic anti-inflammatory input...[(2*)][(4*)]
Sa2011. . . . Vagal Tone is a Non-Invasive Predictor...[(2*)]
Sa2012. . . . Behavioral despair associated with a mouse model...[(4*)]
Sa2013. . . . Anatomical Connections in the Brain Based on Body Mass Index...[(2*)][(4*)]
Sa2014. . . . IBS patients show altered brain responses...[(2*)]
Sa2015. . . . Traumatic Brain Injury and Intestinal Dysfunction...[(2*)]
Sa2016. . . . Translocation of Enteric Bacteria, Colonic Dismotility...[(2*)]
Sa2017. . . . Inhibition of endogenous nitric oxide...[(2*)]
Sa2018. . . . Nitric oxide: A possible mechanism...[(2*)]
Sa2019. . . . GLP-1R expression increases in the enteric nerve system...[(2*)] Shandong Provincial Natural Science Foundation, China [No.ZR2009QL047], the Scientific Research Foundation for Returned Scholars, and the Ministry of Education of China (2011, 43th), and project of Shandong Province Higher Educational Science and Technology Program, No. J14LK15.
Sa2020. . . . Nutrient-Neural Signaling in the Proximal Colon...[(6*)][(2*)]
Sa2021. . . . The stress hormone urocortin 1 induces gastric dysfunction...[(5*)]
Sa2022. . . . Subliminal esophageal acid exposure is associated with...[(4*)]
Sa2023. . . . Electrical stimulation of the abdominal vagus nerve...[(2*)]
Sa2024. . . . Inhibition of ghrelin-O-acetyltransferase...[(2*)][(4*)][(6*)]
Sa2025. . . . Patients with irritable bowel syndrome...[(2*)]
Sa2026. . . . GABA and Glycine Synapses...[(2*)]
Sa2027. . . . Brain activation and food intake reduction...[(3*)][(2*) Tsumura & Co.
Sa2028. . . . Activation of vagal afferent input correlates...[(2*)][(4*)]
Sa2029. . . . Consumption of wheat alpha-amylase/trypsin inhibitors...[(4*)]
Sa2030. . . . Fermented milk product containing B. lactis CNMC I-2494...[(3*)][(4*)] Danone Nutricia Research
Sa2031. . . . The effects of two weeks symbiotic supplementation...[(5*)]
Sa2032. . . . Salmonella infection inhibits intestinal biotin uptake...[(2*)]
Sa2033. . . . Effect of chronic alcohol exposure...[(2*)]
Sa2034. . . . Autoimmune gastritis is common...[(5*)]
Sa2035. . . . Vitamin D and Diverticular Disease...[(5*)]
Sa2036. . . . Deficiency and insufficiency of magnesium and vitamin D...[(5*)]
Sa2037. . . . Prevalence of Vitamin B12 Deficiency...[(5*)]
Sa2038. . . . The Effect of Pancreatic Mass Lesions...[(5*)]
Sa2039. . . . Frequency and significance of abnormal pancreatic imaging...[(5*)]
Sa2040. . . . Pancreatic Adenocarcinoma is Associated with...[(2*)]
Sa2041. . . . Predictors of Lymph Nodal Metastases...[(5*)]
Sa2042. . . . Identification of Proteins by the SOMAscanTM Assay...[(5*)]
Sa2043. . . . Inherent single nucleotide variants...[(5*)]
Sa2044. . . . Investigation of novel multivariate index...[(3*)] Aijinomoto Co., Inc., Kanagawa, Japan
Sa2045. . . . Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms...[(5*)]
Sa2046. . . . Vascular enhancement pattern of mass...[(4*)]
Sa2047. . . . Does Reduced Dose of FOLFIRINOX...[(5*)]
Sa2048. . . . Efficacy and safety of everolimus...[(5*)]
Sa2049. . . . Significance of prognostic nutritional index...[(5*)]
Sa2050. . . . Screening for pancreatic cancer in familial...[(5*)]
Sa2051. . . . Expression and clinical significance of pancreatic cancer...[(4*)]
Sa2052. . . . Efficacy of Minnelide And Paclitaxel Combination...[(2*)]
Sa2053. . . . Validity of 18F-FDG PET/CT Scan for Detection...[(5*)]
Sa2054. . . . Influence of diabetes mellitus...[(5*)]
Sa2055. . . . High-Intensity Focused Ultrasound (HIFU) therapy...[(5*)]
Sa2056. . . . Increasing inpatient burden of Pancreatic Cancer...[(5*)]
Sa2057. . . . Effects of Ethanol, Insulin and Tumor Microenvironment...[(2*)]
Sa2058. . . . Hippo-YAP signaling pathway modulates...[(4*)][(2*)]
Sa2059. . . . Ductal Dilatation As a Sign of Pancreatic Adenocarcinoma...[(5*)]
Su1062. . . . Placebo response and remission rates in ulcerative colitis...[(5*)]
Su1063. . . . Both Medications and Comorbidities can Compromise...[(5*)]
Su1064. . . . Pain hypersensitivity among women with gastroesophageal reflux...[(1*)]
Su1065. . . . Fluctuating Celiac Disease Related Autoimmunity...[(2*)]
Su1066. . . . Rising Incidence of Clostridium difficile...[(5*)]
Su1067. . . . Risk of Clostridium difficile infection...[(5*)]
Su1068. . . . Emergency department visits for acute pancreatitis...[(5*)]
Su1069. . . . Esophageal variceal bleeding in hospitalized patients...[(5*)]
Su1070. . . . Incidence of inflammatory bowel diseases...[(5*)]
Su1071. . . . Registry on the management of acute diarrhea...[(3*)] This study was funded by an unrestricted grant of Sanofi Group (France).
Su1072. . . . Comparison of complications for covered versus uncovered...[(5*)]
Su1073. . . . The SOLE Survey: disease related concerns...[(3*)] AbbVie srl

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CFTA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1074. . . . Risk factors on the development...(4*)[(2]
Su1075. . . . Factors determining adenoma detection rate...(3*) Norgine Ltd.
Su1076. . . . The outcome and role of drugs in patients...(5*)
Su1077. . . . Hazards and Complications of Colonoscopy...(5*)
Su1078. . . . Cholecystectomy and risk of cholangiocarcinoma...(5*)
Su1079. . . . Changes in the Incidence and Prevalence of Cirrhosis...(5*)
Su1080. . . . Increased risk of work disability...(4*)[(3] MSD, Denmark, Ferring Pharmaceuticals
Su1081. . . . Efficacy and safety of multimodality endoscopic therapy...(5*)
Su1082. . . . Changing trends in the characteristics...(5*)
Su1083. . . . Spectrum of cancer phenotypes in Asian Lynch syndrome...(5*)
Su1084. . . . The prevalence of Barrett’s esophagus in Asian Countries...(5*)
Su1085. . . . Prevalence and associations of gastro esophageal reflux...(2*)
Su1086. . . . Multiple in-hospitals transfers...(5*)
Su1087. . . . Fecal microbiota transplant in treatment...(5*)
Su1088. . . . A Novel Predictive Association between Irritable Bowel...(5*)
Su1089. . . . Concurrent Obesity, Diabetes, and Nonalcoholic Fatty Liver...(5*)
Su1090. . . . Gastroesophageal Reflux Disease Prevalence...(4*) This Project did not receive industry or commercial funding.
Su1091. . . . Pregnancy Outcome in Women Treated with Adalimumab...(3*) AbbVie Laboratories
Su1092. . . . Age of onset is associated with seasonality...(5*)
Su1093. . . . Is There Any Association of Diabetes With Individuals...(4*)
Su1094. . . . A Systematic Review and Meta-Analysis of Non-Invasive...(2*)
Su1096. . . . Picosulphate/Magnesium Citrate...(5*)
Su1097. . . . Acute coronary syndrome and risk of gastrointestinal...(5*)
Su1098. . . . Colonoscopies are not safe in patients...(5*)
Su1099. . . . Diet Liberalization and Effects on Bowel Preparation...(5*)
Su1100. . . . A Systematic Review of Patient-Oriented Educational...(4*)
Su1101. . . . Investigating the Smoking Gun...(5*)
Su1102. . . . Consensus Statements on the Management of...(3*) Ferring Pharmaceutical - Shire Pharmaceutical - Olympus Australia - CR Kennedy
Su1103. . . . Introducing non-financial conflicts of interest...(5*)
Su1104. . . . Disregulation of SLC9A3 function...(2*)[(6]
Su1105. . . . Eosinophilic Esophagitis: Analyzing...(4*)
Su1106. . . . Esophageal basophil infiltration is a novel marker...(5*)
Su1107. . . . Loss of expression of the matricellular protein...(5*)
Su1108. . . . Decreased Expression of Damaged DNA-Binding Protein-2...(5*)
Su1109. . . . The Eosinophil Peroxidase (EPO) Brush Assay...(6*)
Su1110. . . . IL-13-induced Dilated Intracellular Space...(2*)[(6]
Su1111. . . . Role of CD24 in Mucosal inflammation...(4*)
Su1112. . . . A set of clinical and endoscopic features...(2*)
Su1113. . . . In search of a non-invasive blood test...(2*)
Su1114. . . . Autophagy-Related Gene 7 (ATG7) may serve...(2*)[(7]
Su1115. . . . Dilated Intracellular Spaces...(4*)
Su1116. . . . Prospective Study Evaluating Diagnostic...(6*)
Su1117. . . . A Novel Method to Diagnose and Monitor Eosinophilic Esophagitis...(4*)
Su1118. . . . Eosinophilic esophagitis is characterized...(4*)
Su1119. . . . Increased rates of low bone mineral density...(4*)
Su1120. . . . Relationship of Quality of Life...(2*)[(3] FALK, Nestle, Aptalis, Receptos, Regeneron, GSK
Su1121. . . . IgG4 reactivity characterizes a subpopulation...(4*)
Su1122. . . . Familial Risk of Eosinophilic Gastrointestinal...(5*)
Su1123. . . . Milk-Specific Immunoglobulin Free Light...(3*)[(7] Nutricia
Su1124. . . . Evaluation of the CRTH2 pathway...(3*)
Su1125. . . . Clinical and High Resolution Manometry Data...(5*)
Su1126. . . . A Pilot Study: Oral Nitric Oxide levels...(5*)
Su1127. . . . Are changes in gene expression limited...(3*) Diagnovus
Su1128. . . . Evaluating gastric cancer risk by using serum...(5*)
Su1129. . . . H. pylori second-line rescue therapy...(5*)
Su1130. . . . Second-line rescue therapy with levofloxacin...(5*)
Su1131. . . . Fourth-line rescue therapy with rifabutin...(5*)
Su1132. . . . Helicobacter pylori first-line and rescue treatments...(5*)
Su1133. . . . Pan-European Registry...Bacterial Resistance...(5*)
Su1134. . . . Pan-European Registry...Safety...(5*)
Su1135. . . . Pan-European Registry...Rescue Treatments...(5*)
Su1136. . . . Pan-European Registry...Interim Analysis...(5*)
Su1137. . . . The recurrence and clarithromycin resistant rate...(4*)
Su1138. . . . Concomitant therapy appeared superior...(2*) Basic Science Research Program through the National Research Foundation of Korea (NRF) Grant No. 2013R1A1A2062603.

Abstract Funding Source Key

*(*) = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1200. . . . The contribution of clinical factors, serology...(5*) Prometheus laboratories performed the measurements of pANCA and the different antimicrobial antibodies. They were not involved in the processing and the statistical analysis of the results or the conclusions in this abstract.

Su1201. . . . Proximity Extension Assay technology...(2*)

Su1202. . . . Utility of Emergency Room Use...(5*)

Su1203. . . . Lamina Propria T helper Cell Subsets...(4*)

Su1204. . . . Association between eleven thiopurine metabolites...(5*)

Su1205. . . . Ulcerative colitis patients with and without subclinical...(7*) Alberta Innovates Bio Solutions


Su1207. . . . Diagnosis of ulcerative colitis-associated intraepithelial...(5*)

Su1208. . . . What factors influence poor bowel preparations...(5*)

Su1209. . . . Upper Gastrointestinal Involvement of Crohn’s Disease...(5*)

Su1210. . . . The prognostic value of the natural killers (NK-cells)...(2*)

Su1211. . . . Serologic responses to microorganisms in IBD patients...(6*)

Su1212. . . . A simplified histological Geboes Score for ulcerative colitis...(5*)

Su1213. . . . Is CRP the herald of disease activity...(5*)

Su1214. . . . Inflammatory bowel disease associates with pro-inflammatory...(2*)

Su1215. . . . SMAD4 expression is downregulated...(4*)

Su1216. . . . Low Fecal Calprotectin Correlates With...(5*)

Su1217. . . . Quantification of mucosal polyunsaturated fatty acid...(2*)

Su1218. . . . Cigarette Smoke Extract Differentially Affects Expression...(4*)

Su1219. . . . Serum neutrophil gelatinase B-associated lipocalin...(2*)[4]

Su1220. . . . Rectal bleeding accurately reflects...(3*) Both the EMBARK1 and Eucalyptus2 studies were sponsored by Genentech Inc.

Su1221. . . . Symptom scores do not accurately reflect...(3*) The EMBARK study was sponsored by Genentech Inc.

Su1222. . . . Elevated alkaline phosphatase as a marker...(5*)

Su1223. . . . Measurement of Inflammatory Bowel Disease...(2*)

Su1224. . . . Small bowel mucosal healing and deep remission...(6*)

Su1225. . . . Natural History of Radiologic Responders in Patients...(5*)

Su1226. . . . Evolution of the Lémann Index...(1*)

Su1227. . . . Diffusion-weighted magnetic resonance....is highly effective...(5*)

Su1228. . . . Diffusion-Weighted magnetic resonance...before treatment...(5*)

Su1229. . . . Definitions of the endoscopic lesions in Crohn’s disease...(5*)

Su1230. . . . Remote monitoring of IBD disease activity...(4*)

Su1231. . . . Luminal nitric oxide and plasma nitrre/nitrate...(4*)[2]

Su1232. . . . Persistent anemia in Inflammatory Bowel Disease...(2*)[3] Janssen Services, LLC.

Su1233. . . . Five year trends in Harvey Bradshaw Index scores...(2*)[3] Janssen Services, LLC. Mean sIBDQ to stratify Crohn’s disease patients: Impact of neuropsychiatric illness, chronic pain and refractory inflammation.

Su1234. . . . Histologic correlates of clinical and endoscopic severity...(2*)

Su1235. . . . Monitoring of histologically defined healing...(3*) TechLab research grant

Su1236. . . . High Fecal Calprotectin Correlate With...(5*)

Su1237. . . . Evolution of the Lemann index in Crohn’s disease...(5*)

Su1238. . . . Contrast-enhancement at magnetic resonance enterography...(5*)

Su1239. . . . Underestimation of Ulcerative Colitis Disease Severity...(3*)

Su1240. . . . Comparison of rectosigmoidoscopy and colonoscopy...(3*)

Su1241. . . . Circulating Alpha-1 Antitrypsin...(5*)

Su1242. . . . Serum REG Ia is a marker to predict histological...(5*)

Su1243. . . . Evaluation and long-term benefit of mucosal healing...(5*)

Su1244. . . . Accuracy of fecal M2-Pyruvate Kinase...(1*)

Su1245. . . . Modifying and validating endoscopic and magnetic resonance...(4*)


Su1247. . . . Psychometric Evaluation of the Signs and Symptoms...(3*) Amgen Inc. Genentech Inc.

Su1248. . . . Fecal immunochemical test versus fecal calprotectin...(5*)

Su1249. . . . Evaluation of NT-proBNP in Inflammatory Bowel...(4*)

Su1250. . . . Development of a patient reported disease activity score...(5*)

Su1251. . . . Accuracy of a rapid fecal calprotectin test...(5*)

Su1252. . . . Limitations in using fecal Calprotectin as a biomarker...(5*)

Su1253. . . . Pooled Analysis of Symptom Resolution...(3*) Research was funded by Shire Development LLC.

Su1254. . . . Predictors Of 30 Day Readmission Rates...(5*)

Su1255. . . . Fecal calprotectin is elevated with clinical disease activity...(4*)[6]

Su1256. . . . Impact of Magnetic Resonance Enterography...(5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCF, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1257. . . . . . The Gene Expression of SPARC in the Colonic Mucosa... (4*)
Su1258. . . . . . Effect of MMX-mesalazine (Mezavant XL ®)... (1*) (3) This study is supported by Shire Inc.
Su1259. . . . . . Additional item of Fecal Hemoglobin as a Marker... (5*)
Su1260. . . . . . Inflammatory Bowel Disease activity is inversely correlated... (2*)
Su1261. . . . . . Serum TNF-α level changes during pregnancy... (4*)
Su1262. . . . . . Downregulation of IL-17 related cytokines... (5*)
Su1263. . . . . . Clostridium difficile Infection remains an independent... (5*)
Su1264. . . . . . Prevalence, causes and impact of abnormal liver... (5*)
Su1265. . . . . . Risk Factors and Cumulative Incidence of Osteoporosis in Patients... (4*)
Su1266. . . . . . Characterization of Incident Cases of Cancer... (5*)
Su1267. . . . . . Poor Recognition and Management of Iron Deficiency... (5*)
Su1268. . . . . . Serum vitamin D binding protein concentration... (3*) Ferring Pharmaceutical Australia provided a limited research grant.
Su1269. . . . . . Preoperative Anti TNF α Therapy... (5*)
Su1270. . . . . . Incidence of avascular necrosis of the hip... (5*)
Su1271. . . . . . Risk matrix for prediction of disease progression... (5*)
Su1272. . . . . . Presence of anti-MZGF2 IgG and IgA... (5*)
Su1273. . . . . . Incidence and Predictors of Recurrence and Re-hospitalization... (5*)
Su1274. . . . . . Differential protein expression profiles... (6*) (2)
Su1275. . . . . . Prevalence of extraintestinal manifestations... (2*)
Su1276. . . . . . Use of Anti-TNF Therapy in patients... (4*)
Su1277. . . . . . Consistently Low Albumin Level as a Predictor... (4*) (2)
Su1278. . . . . . Heterogeneity in the Endoscopic Management... (5*)
Su1279. . . . . . Vitamin B12 Deficiency in Inflammatory Bowel... (5*)
Su1280. . . . . . Impaired intestinal barrier function contributes... (4*)
Su1281. . . . . . Quantitative real-time PCR for the detection... (5*)
Su1282. . . . . . Endoscopic detection of small bowel adenocarcinoma... (6*) (7)
Su1283. . . . . . Does autonomic dysfunction contribute... (2*) (3) Janssen Services, LLC.
Su1284. . . . . . Risk factors for active tuberculosis... (5*)
Su1285. . . . . . Lymphoma and Skin cancers rates... (2*)
Su1286. . . . . . Incidence of Clostridium difficile in Hispanics... (4*)
Su1287. . . . . . Anal neoplasia in inflammatory bowel disease... (5*)
Su1288. . . . . . Patients with Coexistent Celiac Disease and Inflammatory Bowel... (4*) This study was funded by Centre for Excellence of Gastrointestinal Inflammation and Immunity Research (CEGIR), University of Alberta Hospital Foundation Kimberley Homes IBD fund, Alberta IBD Consortium.
Su1289. . . . . . Prevalence of low bone mineral density in adult... (5*)
Su1290. . . . . . Endoscopic Balloon Dilation for Crohn’s Related Strictures... (5*)
Su1291. . . . . . Low vitamin D status is an independent predictor... (5*)
Su1292. . . . . . The long-term influence of anti-TNF agents... (2*) (3) Janssen Services, LLC.
Su1293. . . . . . Neuroimaging Changes and Behavioral Correlates... (4*)
Su1294. . . . . . Clinical Features and Prognosis of Coexisting Inflammatory Bowel... (4*)
Su1295. . . . . . Risk and clinical characteristics of colorectal cancers... (4*)
Su1296. . . . . . Increase of Inflammatory Bowel Disease incidence in teenagers... (5*)
Su1297. . . . . . Caesarian section is not a risk factor for the development... (5*)
Su1298. . . . . . Early detection of Clostridium difficile... (2*)
Su1299. . . . . . Smoking is associated with extra-intestinal manifestations... (3*) Unrestricted grant from AbbVie.
Su1300. . . . . . Healthcare expenditures for inflammatory bowel... (3*) Unrestricted grant from AbbVie.
Su1301. . . . . . Incidence and Phenotype of Inflammatory Bowel... (3*) Unrestricted educational grant from Ferring pharmaceuticals.
Su1302. . . . . . Comparison of Disease Phenotype in 35,128 European... (5*)
Su1303. . . . . . Prevalence and Disease Characteristics of Inflammatory... (6*) (3) Unrestricted educational grant from AbbVie.
Su1304. . . . . . Factors associated with delayed initiation of IBD medication... (5*)
Su1305. . . . . . Surgery and hospitalization rates during the first year... (5*)
Su1306. . . . . . Treatment strategy during the first year... (5*)
Su1307. . . . . . Neoplasia risk after colectomy in inflammatory bowel... (5*)
Su1308. . . . . . Predictors of 30 day Readmissions in Patients... (5*)
Su1309. . . . . . The age dependent effect of smoking... (4*)
Su1310. . . . . . Pregnancy And Birth Rates Are Decreased Among Women... (5*)
Su1311. . . . . . Mortality in Crohn’s disease and ulcerative colitis... (4*)
Su1312. . . . . . The first prospective Australian population-based study... (4*)
Su1313. . . . . . Epidemiology and characteristics of inflammatory bowel... (5*)
Su1314. . . . . . Prevalence and characteristics of anemia... (2*) (3) Janssen Services, LLC.
Su1315. . . . . . Characterization of inflammatory bowel disease... (4*)
Su1316. . . . . . Unchanged surgery and hospitalization rates... (4*) (7)
Su1317. . . . . . Childlessness in IBD Patients... (5*)
Su1318. . . . . . Feasibility of collecting biospecimens... (6*) (2) (3) GlaxoSmithKline Worldwide Epidemiology

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds   (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFRA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1319. . . . Immunosuppression Increases the Odds...*(5)*
Su1320. . . . Prevalence of impaired muscle strength...*(5)*
Su1321. . . . Coliform colonization and infection rates are now low...*(5)|(4)*
Su1322. . . . Inflammatory Bowel Disease: Trends in Hospitalizations...
Su1323. . . . Patients with Crohn's Disease who Never Smoke...*(2)*
Su1324. . . . Adherence to medical therapy and to follow up...*(5)*
Su1325. . . . The Prevalence and Impact of Mood Disorders...
Su1326. . . . IBD in migrant South Asian populations...*(5)*
Su1327. . . . Keep or Destroy? Attitudes of Patients...*(6)*[3] Investigator initiated small grant funding from Glaxo.
Su1328. . . . Fertility in IBD women is comparable to...*(5)*
Su1329. . . . Evolution after anti-TNF drug discontinuation...*(5)*
Su1330. . . . Seasonal variations among hospitalizations...*(2)*
Su1331. . . . Strictureing/Penetrating Crohn's disease at diagnosis...*(4)*[6][3] AbbVie and Schering Plough
Su1332. . . . Long-term Outcome of Patients with Crohn’s Disease...*(2)* This study was financially supported in part by National Key Clinical Department in Ministry of Public Health, China (No.30304269002), Scientific Project of Guangzhou, China (No. 20111Y-00004), and the National Natural Science Foundation of China (NSFC grant No. 8147082120577040 and 81270473).
Su1333. . . . Disease course, phenotype, and medication use...*(5)*
Su1335. . . . A Novel Description of Longitudinal Phenotype...*(4)*[2]
Su1336. . . . The Pre-diagnosis Inflammatory Signature...*(4)*[2]
Su1337. . . . Disease progression is a risk factor for colectomy...*(5)*
Su1338. . . . The association between serum phospholipid oleic...*(6)*
Su1339. . . . The Frequency of Steroid Use in Patients...*(5)*
Su1340. . . . Temporal relationship Between Onset of Ulcerative Colitis...*(5)*
Su1341. . . . Radiologic and Clinical Features as Predictors...*(5)*
Su1342. . . . Is Thiopurine Therapy More Successful in Ulcerative Colitis...*(5)*
Su1343. . . . Increased intestinal tissue IgG4+ plasma cells...*(2)*
Su1344. . . . IBD symptoms, religiosity, and health locus of control...*(2)*
Su1345. . . . Vitamin D Malabsorption Is Associated With...*(5)*
Su1346. . . . Pregnancy-Onset IBD Is Not Associated With...*(5)*
Su1347. . . . A measurement of risk score to predict the need of surgery...*(5)*
Su1348. . . . Analysis of Microbiota and Metaboloma...*(5)*
Su1349. . . . Predictive Value of the “DICA”...*(5)*
Su1350. . . . Characteristics of high resolution anorectal manometry...*(5)*
Su1351. . . . Quality of Life in Lymphocytic and Collagenous Colitis...*(5)*
Su1352. . . . Detection of Clostridium Difficile-Infected Stool...*(5)* The Aetholab and disposable specimen bottles were provided by The eNose Company (Zutphen, NL). No additional funding was otherwise provided.
Su1353. . . . Outcomes of Patients with Microscopic Colitis...*(5)*
Su1354. . . . Endoscopic findings and predictive factors for operation...*(5)*
Su1355. . . . Perception of lactose intolerance impairs health...*(5)*
Su1356. . . . Does carbohydrate challenge testing predict clinical response...*(5)*
Su1357. . . . Underweight Patients with C. difficile infection...*(5)*
Su1358. . . . Metabolic Syndrome Factors and the Risk of Diverticulosis...*(5)*
Su1359. . . . Long term retrograde rectal cleansing in patients...*(5)*
Su1360. . . . Different perception of constipation between patients and gastroenterologists...*(1)*
Su1361. . . . The Comparison of Clinical Outcomes of Pseudomembranous...*(5)*
Su1362. . . . Indeterminate for GVHD: clinical and endoscopic correlation...*(5)*
Su1363. . . . Resolution of bacterial and food protein-induced diarrhea...*(5)*
Su1364. . . . The Survey for the Role of Dietary Factors...*(2)*
Su1365. . . . Characterization of Chronic Diarrhea in Patients...*(5)*
Su1366. . . . Treatment with recombinant Trichinella spiralis cathepsin B-like...*(2)*
Su1367. . . . Faecal human beta-defensin 2 levels in children...*(6)*[7]
Su1368. . . . Undernutrition and Altered Gut Secretory IgA...*(6)*[2]
Su1369. . . . Gut-directed hypnotherapy and a low FODMAP diet...*(6)*[4]
Su1370. . . . Diagnostic Accuracy of a Brief IBS Screener...*(4)*[2]
Su1371. . . . Non-Traumatic Stressful Events...*(2)*
Su1372. . . . IBS is a syndrome of inter-related symptoms...*(3)* IMHealthScience
Su1373. . . . Ibgard®, a novel small intestine targeted delivery system...*(3)* IM HealthScience, LLC.
Su1374. . . . Differences in Nutrient Intake Between...*(4)*
Su1375. . . . Healthcare cost of irritable bowel syndrome...*(5)*
Su1376. . . . Assessment of IBS-D severity...*(3)* Menarini Ricerche Spa - Menarini Group
Su1377. . . . Efficacy of Oral Ibdutant in IBS-D Female Patients...*(3)* Menarini-Ricerche Spa
Su1378. . . . Robustness of Extraludoline for the Treatment...*(3)* Studies sponsored by Furiex Pharmaceuticals, a subsidiary of Actavis plc. Editorial support provided by Complete HealthVizion.

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NHI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1379. . . Using the FDA Composite Endpoint for IBS-D...[3*] Prometheus Laboratories Inc.

Su1380. . . Consistency in Efficacy Outcomes of Eluxadoline-treated...[3*] Studies sponsored by Furiex Pharmaceuticals, a subsidiary of Actavis plc. Editorial support provided by Complete HealthVizion.

Su1381. . . Autoprobiotic: place in the prevention of postinfectious...[5*]

Su1382. . . Prevalence of gastrointestinal symptoms...[5*]

Su1383. . . Effects of Eluxadoline on Abdominal Pain in Patients...[3*] Studies sponsored by Furiex Pharmaceuticals, a subsidiary of Actavis plc. Editorial support provided by Complete HealthVizion.

Su1384. . . A Retrospective Assessment of Area under the Pain Curve...[3*] Studies sponsored by Furiex Pharmaceuticals, a subsidiary of Actavis plc. Editorial support provided by Complete HealthVizion.

Su1385. . . Effect of Eluxadoline on Health-related Quality of Life...[3*] Studies sponsored by Furiex Pharmaceuticals, a subsidiary of Actavis plc. Editorial support provided by Complete HealthVizion.

Su1386. . . Clinical benefit and intestinal mucosal transcriptome modulation...[2*][4]

Su1387. . . Colon Loops and their association with Irritable Bowel...[5*]

Su1388. . . Stigmatizing Beliefs Toward the Irritable Bowel Syndrome...[5*]

Su1389. . . Irritable Bowel Syndrome Symptom Overlap in Patients...[1*]

Su1390. . . Effects of low-Fodmap diet and rifaximin...[5*]

Su1391. . . Psychological state of subjects with irritable bowel...[5*]

Su1392. . . The Correlation Between Nesfatin-1 and Stress...[5*]

Su1393. . . Prevalence and self-recognition of chronic constipation...[5*]

Su1394. . . Limited utility of generic, serum-based fibrosis scores...[3*] Gilead Sciences

Su1395. . . Eligibility of a Real World Population for Phase 3 Clinical Trials...[5*]

Su1396. . . Frequency and prognosis of acute pancreatitis...[5*]

Su1397. . . Very Low and Similar Proportions of Patients...[5*]

Su1398. . . Immune Response to Recombinant Hepatitis B Vaccine...[5*]

Su1399. . . Rationale for antiviral therapy for hepatitis C...[5*]

Su1400. . . An open labelled, active controlled study...[5*]

Su1401. . . Treatment of HCV Using Combination DAAs...[5*]

Su1402. . . Etiology And Natural Course Of End-Stage Liver Disease...[5*]

Su1403. . . Medical, Social, and Legal Risks to Predict Alcoholic Liver...[2*]

Su1404. . . Attitudes and Perceptions of Chronic Hepatitis C Virus...[3*] Merck Investigator Studies Program (MISP)

Su1405. . . Setting and Documentation of Hepatitis C Virus Antibody Testing...[3*] Merck Investigator Studies Program (MISP)

Su1406. . . Intrafamilial transmission of chronic HBV infection...[4*][7]

Su1407. . . Risk factors associated with Chronic Hepatitis B infection...[4*][7]

Su1408. . . Effect of risk factors on severity of Anti tuberculous...[5*]

Su1409. . . Eight-week community based program is associated with...[1*]

Su1410. . . New treatments for chronic hepatitis C...[5*]

Su1411. . . Seroclearance of Surface Ag in Genotype D Chronic Hepatitis B...[4*][7]

Su1412. . . Colitis following initiation of sofosbuvir and simeprevir...[5*]

Su1413. . . MICRB (MHC class I-related chain B) gene polymorphism...[5*]

Su1414. . . A Randomized Controlled Trial to Compare the Efficacy and Safety...[2*]

Su1415. . . Clinical Usefulness of Red Cell Distribution Width...[4*]

Su1416. . . Patient Reported Outcomes (PROs) in Chronic Hepatitis C...[5*]

Su1417. . . A Meta-analytic Estimation of the Burden of Extra Hepatic...[5*]

Su1418. . . Success Of Gastric Electrical Stimulation...[3*] Medtronic

Su1419. . . Enterra stimulation for gastroparesis...[5*]

Su1420. . . Evaluating Gastric Mucosal Nerve Density...[2*][1]

Su1421. . . The Electrogastrogram Analysed by Quantitative Signal...[1*]

Su1422. . . Autonomic And Enteric Responses to Temporary Gastric Electrical Stimulation...[2*][1]

Su1423. . . Epidemiology of Gastroparesis...[5*]

Su1424. . . Diagnostic Criteria for Gastroparesis...[5*]

Su1425. . . Effects of high-frequency gastric electrical stimulation...[2*]


Su1427. . . Gastric Electrical Stimulation of the Antrum...[4*]

Su1428. . . Wireless Motility Capsule Gastric and Extra gastric Transit...[2*]

Su1429. . . Regression to the Mean and Treatment Effects in Gastroparesis...[5*]

Su1430. . . Acute effects of botulinum toxin on pyloric pressure...[5*]

Su1431. . . Abdominal Pain in Gastroparesis...[2*]

Su1432. . . Subjective Factors and Impact on Quality of Life...[5*]

Su1433. . . Coexisting Psychiatric Disorder Predicts...[5*]

Su1434. . . Gastric dysmotility and its relationship...[5*]

Su1435. . . The role of insulin and IGF-1 signaling passway...[2*]

Su1436. . . Central Versus Peripheral Sites of Action...[3*] Helsinn Healthcare, SA, Lugano Switzerland and Helsinn Therapeutics (US), Inc.

Su1437. . . Measuring gastric and small bowel motility in patients...[4*]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds   (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds   (5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CIFTA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1438. . . . Noninvasive biomagnetic assessment of the effects...(2*)

Su1439. . . . Foods Provoking and Allieving Symptoms...(1*)

Su1440. . . . Diabetes-related Autoantibodies in Diabetic Patients...(5*)

Su1441. . . . Increasing Inpatient burden of Gastroparesis...(5*)

Su1442. . . . Patient Related Factors (Patient Activation and Health Locus of Control)...(5*)

Su1443. . . . Gastric Neuromuscular Pathology and Therapeutic Outcome...(5*)

Su1444. . . . Analysis of Intestinal Cells of Cajal in Pyloric Smooth Muscle...(5*)

Su1445. . . . A Finite-State Machine Model for Real-time Analysis...(4*)

Su1446. . . . Randomized Double-Blind Placebo-Controlled Pilot Study...(5*)

Su1447. . . . Short term non-invasive afferent vagus nerve stimulation...(5*)

Su1448. . . . MENG reveals intestinal slow wave dysrhythmia...(2*)

Su1449. . . . Incidence and clinical significance of delayed gastric...(2*)

Su1450. . . . Gastric mucosal innervation in endoscopic biopsies...(2*)

Su1451. . . . Dynamic Antral Scintigraphy Identifies Patterns...(4*)

Su1452. . . . Analyses of Long-term Follow-up of Gastric Electrical...(5*)

Su1453. . . . Papaya enzyme supplements in symptomatic patients...(5*)

Su1454. . . . Is Gastroparesis a Panenteric Neuropathic Disorder...(5*)

Su1455. . . . Relationship of Gastric Emptying...(5*)

Su1456. . . . Adult cancer patients with intestinal failure...(6*)|(7)

Su1457. . . . Hospital admissions in adult intestinal failure patients...(6*)|(7)

Su1458. . . . Intestinal transplantation for short bowel syndrome...(5*)

Su1459. . . . Serum N-Glycan Profiles in Patients...(2*)

Su1460. . . . MicroRNAs for the Differentiation...(7*)

Su1461. . . . Epidemiology of Solid Pseudopapillary Neoplasm...(5*)

Su1462. . . . Follow-up of Asymptomatic Pancreatic Cysts...(5*)

Su1463. . . . Risk of Pancreatic Malignancies in Patients...(5*)

Su1464. . . . Features Associated with Interval Progression...(5*)

Su1465. . . . Prognosis of Non-surgery Patients with High-risk...(5*)

Su1466. . . . The Value of KRAS Mutation testing with CEA...(5*)

Su1467. . . . Success of endoscopic ultrasound-guided ethanol ablation...(5*)

Su1468. . . . Mural nodule of 10mm or larger as predictor...(5*)

Su1469. . . . Long Term Surveillance of Low-Intermediate Risk...(5*)

Su1470. . . . Predictive factors for disease progression...(1*)

Su1471. . . . Clinical observation is possible for branch duct...(5*)

Su1472. . . . Follow up of Branch Duct Intraductal Papillary Mucinous...(1*)

Su1473. . . . Risk factor for appearance of invasive carcinoma during follow up...(7*)

Su1474. . . . Outcome of over 1 year follow up cases...(5*)

Su1475. . . . Prevalence of Pancreatic Cystic Lesions...(5*)

Su1476. . . . Plectin-1 as a biomarker for malignant progression...(5*)

Su1477. . . . Advances in high resolution cross section imaging...(5*)

Su1478. . . . The natural history of small incidental pancreatic cysts...(5*)

Su1479. . . . Prognostic factors of elderly patients with IPMNs...(5*)

Su1480. . . . Cyst Fluid Amphiregulin May Predict...(7*)

Su1481. . . . Cystic Lesions of the Pancreas...(5*)

Su1482. . . . ePiCC (Electronic Pancreatic Cyst Clinic)...(5*)

Su1483. . . . Novel Metabolomics Markers for Characterization...(4*)

Su1484. . . . Brachial duct intraductal papillary mucinous neoplasm...(5*)

Su1485. . . . Validation of a 9-microRNA panel in pancreatic cyst fluid...(5*)

Su1486. . . . Patient anxiety, awareness, and preferences...(5*)

Su1822. . . . Alteration of Murine Intestinal Microbiota...(2*)|(4)

Su1823. . . . Down-regulation of IncRNA NR_033122...(2*)

Su1824. . . . Helicobacter pylori alters p53 stress response...(2*)

Su1825. . . . Helicobacter pylori infection induces anemia...(2*)

Su1826. . . . Pseudokinase Tribbles 3 enhances SHP2-dependent...(2*)

Su1827. . . . High Prevalence of Atrophic Autoimmune Gastritis...(4*)

Su1828. . . . MiR-155 expression in Helicobacter pylori...(2*)|(4)

Su1829. . . . Bioinformatic approach to mapping...(2*)

Su1830. . . . Immunization combined with inhibiting...(2*)|(3) Therinject LLC provided nanoparticles as a biological response modifier.

Su1831. . . . Toll-like receptor 9 suppresses the progression...(2*)

Su1832. . . . Analysis of autophagy related genes in patients...(5*)

Su1833. . . . Prostate stem cell antigen gene polymorphisms...(5*)

Su1834. . . . Crypt hyperplastic enteropathy in DQ2/DQ7...(5*)

Su1835. . . . Serologically Determined Gastric Mucosal Condition...(2*)

Su1836. . . . Gastric Granulomas and Helicobacter pylori...(4*)

Su1837. . . . The promising risk marker for gastric cancer...(4*)

Su1838. . . . Differential effect of fiber type and fermentability...(3*)|(4) National Pork Board

Su1839. . . . Probiotic administration among free-living older adults...(3*)|(4) BioGaia AB

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds

(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Su1840. . . . Protective effect of Insulin on LPS-induced oxidative stress...[5*)

Su1841. . . . Increased Sucrose But not Starch Intake...[4*)

Su1842. . . . Oral feeding Lactobacillus reuteri DSM17938...[2*)](3) Biogaia AB

Su1843. . . . Assessment of a multi strain probiotic (Symprove)...[3*)](4) Symprove Ltd. provided an unrestricted grant to Kings College Hospital that covered Dr Sissons salary. They also provided the probiotic and placebo free of charge.

Su1844. . . . NHERF2 contains a Phosphorylatable Ezrin...[2*)

Su1845. . . . Molecular Mechanism of Lipopolysaccharide induced increase...[2*)

Su1846. . . . IL-1β induced PDZK1 downregulation...[2*)](4)

Su1847. . . . H19 is an early response long non-coding RNA...[2*)

Su1848. . . . NHE exchanger disruption after short- and long-term...[2*)

Su1849. . . . Involvement of protein kinase A and Rhoa/ROCK pathway...[2*)

Su1850. . . . 5-Fluorouracil-induced intestinal injury...[2*)

Su1851. . . . Clinical Correspondence of S100 Levels...[1*)

Su1852. . . . The 5-HT4 Selective Agonist Prucalopride...[4*)

Su1853. . . . Effects of Experimental Ulcerative Colitis...[2*)

Su1854. . . . Molecular Mechanisms of the Mechanosensitivity...[2*)

Su1855. . . . The Frequency-velocity Correlation of Porcine...[2*)

Su1856. . . . High-Resolution Mapping of Slow Wave Activity...[2*)

Su1857. . . . Intracellular activity and characteristic features...[5*)

Su1858. . . . Motor Neurons of Gut Myenteric Plexus...[2*)

Su1859. . . . Incorporation of interstitial cells of Cajal...[2*)](4)

Su1860. . . . Extracellular Chloride (Cl-) Substitution Disrupts...[2*)

Su1861. . . . Postbiotic Protective Activity of Lactobacillus Rhamnosus...[4*)

Su1862. . . . Smooth muscle specific alpha-actin plays a critical role...[2*)

Su1863. . . . High resolution mapping reveals impairment...[4*)

Su1864. . . . Clinical Correspondence of Intestinal Cells...[2*)](1)

Su1865. . . . Motor Effects of Belamorelin on Colonic Functions...[3*)] Research support and drug provided by Rhythm Pharmaceuticals.

Su1866. . . . Neuromechanical factors in the production of faeces...[2*)

Su1867. . . . Simultaneous Anterior and Posterior High-resolution Mapping...[2*)

Su1868. . . . Free fatty acid FFAR1 receptors mediate relaxation...[2*)](4)

Su1869. . . . Effect of DA 9701 on upregulation...[5*)

Su1870. . . . Entacapone, a peripherally restricted COMT inhibitor...[4*)

Su1871. . . . Effects of DA-9701, a prokinetic agent...[5*)

Su1872. . . . High resolution neuronal imaging reveals a novel rhythm...[2*)

Su1873. . . . Dopamine D1 and D2 Receptors...[2*)

Su1874. . . . High and standard protein weight loss diets...[4*)

Su1875. . . . High levels of sulfate-reducing bacteria predispose...[4*)

Su1876. . . . Replacement of Insoluble Fiber (IF) with Soluble Fiber...[5*)

Su1877. . . . Japanese patients with type 2 diabetes...[5*)

Su1878. . . . Microbial Signatures of Persistent Effects...[2*)](6)

Su1879. . . . Microbiota metabolism of soluble fiber...[2*)

Su1880. . . . Metabolic signatures in human serum...[4*)

Su1881. . . . High protein diet improves meal pattern...[2*)

Su1882. . . . Heat Shock Protein 70 Overexpression...[4*)

Su1883. . . . Bile acid metabolism does not change...[4*)

Su1884. . . . Over-expression of Epithelial Cell Heat Shock Protein 70...[4*)

Su1885. . . . Insulin Resistance is a Key Factor for Metabolic...[5*)

Su1886. . . . Long-lasting dipetidyl peptidase-4 inhibitor...[5*)

Su1887. . . . Increased expression of PPARγ in CD24 knockout...[4*)

Su1888. . . . Pancreatic Enzyme Replacement Therapy...[5*)

Su1889. . . . Can We Detect Chronic Pancreatitis...[1*)

Su1890. . . . Local and systemic complications of acute pancreatitis...[5*)

Su1891. . . . Success of Educational Intervention...[3*)] This study was supported by an unrestricted educational grant from AbbVie and conducted by Medscape Education. The authors have no personal or financial disclosures.

Su1892. . . . Cystatin C Attenuates Cathepsin S-Evoked...[2*)

Su1893. . . . Colonic Inflammation Induces Uptregulation...[2*)

Su1894. . . . Identification of a Novel function of Corticotropin Releasing Factor...[2*)

Su1895. . . . Corticotropin-releasing factor (CRF) may protect...[4*)

Su1896. . . . Tenascin-C mediates the suppressive effects...[2*)] Grant-in-aid for Scientific research from the Ministry of education, Japan. No.25221205 to HO, MK&MH.

Su1897. . . . Keratin 8 expression is reduced in active ulcerative colitis...[6*)

Su1898. . . . ATG5, LRRK2, NOD2 autophagy Gene Up-regulation...[4*)

Su1899. . . . Receptor Modulation and MAP-Kinase Signaling...[3*)] Steigerwald Arzneimittelwerk GmbH

Su1900. . . . Portal triad clamping in rats...[2*)

Su1901. . . . Heme oxygenase-1 (HO-1) prevents...[5*)

Su1902. . . . MMP-12 Modulation of Intestinal Epithelial...[4*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds   (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)   (3) = Industry or Commercial Entity   (4) = Institutional Funds
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors (First and Last)</th>
<th>Funding Source Key</th>
</tr>
</thead>
<tbody>
<tr>
<td>Su1975</td>
<td>Altered expression and localization of Dclk1 isoforms</td>
<td>Su9198</td>
<td>5*</td>
</tr>
<tr>
<td>Su1976</td>
<td>Glutamine metabolism as a therapeutic target</td>
<td>Su1998</td>
<td>5*</td>
</tr>
<tr>
<td>Su1977</td>
<td>Roles of Intestine Specific Homebox</td>
<td>Su1999</td>
<td>5*</td>
</tr>
<tr>
<td>Su1978</td>
<td>Polymorphisms in the RELB Gene</td>
<td>Su2001</td>
<td>5*</td>
</tr>
<tr>
<td>Su1979</td>
<td>Detection of Gastric Cancer and Metaplasia</td>
<td>Su2002</td>
<td>5*</td>
</tr>
<tr>
<td>Su1980</td>
<td>Diabetes and dislipidemia increase significantly</td>
<td>Su2003</td>
<td>5*</td>
</tr>
<tr>
<td>Su1981</td>
<td>Endoscopic Evaluation of Families with Hereditary</td>
<td>Su2004</td>
<td>5*</td>
</tr>
<tr>
<td>Su1982</td>
<td>Risk factors of intestinal metaplasia</td>
<td>Su2005</td>
<td>5*</td>
</tr>
<tr>
<td>Su1983</td>
<td>Spatial distribution of Lgr5-positive cancer cells</td>
<td>Su2006</td>
<td>5*</td>
</tr>
<tr>
<td>Su1984</td>
<td>Long Term Prognosis after Non-Curative Endoscopic</td>
<td>Su2007</td>
<td>5*</td>
</tr>
<tr>
<td>Su1985</td>
<td>Impact of surveillance interval in patients</td>
<td>Su2008</td>
<td>5*</td>
</tr>
<tr>
<td>Su1986</td>
<td>Epigenetic and Genetic Inactivation of the E-Cadherin Gene</td>
<td>Su2009</td>
<td>5*</td>
</tr>
<tr>
<td>Su1987</td>
<td>Methylated Reprimo in cell-free DNA (RPRM)</td>
<td>Su2010</td>
<td>5*</td>
</tr>
<tr>
<td>Su1988</td>
<td>Establishment and characterization of isogenic invasive</td>
<td>Su2011</td>
<td>5*</td>
</tr>
<tr>
<td>Su1989</td>
<td>Inhibition of protein phosphatase 2A</td>
<td>Su2012</td>
<td>5*</td>
</tr>
<tr>
<td>Su1990</td>
<td>A new technology for the classification of patients</td>
<td>Su2013</td>
<td>5*</td>
</tr>
<tr>
<td>Su1991</td>
<td>Surveillance Strategy Based on the Incidence</td>
<td>Su2014</td>
<td>5*</td>
</tr>
<tr>
<td>Su1992</td>
<td>Role of Helicobacter pylori-induced hypoxia-inducible factor-1a</td>
<td>Su2015</td>
<td>5*</td>
</tr>
<tr>
<td>Su1993</td>
<td>Somatic mutations in the mismatch repair system</td>
<td>Su2016</td>
<td>5*</td>
</tr>
<tr>
<td>Su1994</td>
<td>Krüppel-like factor 4 (KLF4) is required</td>
<td>Su2017</td>
<td>5*</td>
</tr>
<tr>
<td>Su1995</td>
<td>Proteomic identification of mutant p53 R282W regulated genes</td>
<td>Su2018</td>
<td>5*</td>
</tr>
<tr>
<td>Su1996</td>
<td>Oncogenic BRAFV600E downregulates Dnmt3b</td>
<td>Su2019</td>
<td>5*</td>
</tr>
<tr>
<td>Su1997</td>
<td>Colorectal cancer with methylator phenotype</td>
<td>Su2020</td>
<td>5*</td>
</tr>
<tr>
<td>Su1998</td>
<td>Genomic profile and clinicopathological analysis</td>
<td>Su2021</td>
<td>5*</td>
</tr>
<tr>
<td>Su1999</td>
<td>Proteomic analysis of gallbladder cancer (2*)</td>
<td>Su2022</td>
<td>5*</td>
</tr>
<tr>
<td>Su2000</td>
<td>Clincopathological characterization of duodenal</td>
<td>Su2023</td>
<td>5*</td>
</tr>
<tr>
<td>Su2001</td>
<td>Snail/CXCL-8 axis promotes expression</td>
<td>Su2024</td>
<td>5*</td>
</tr>
<tr>
<td>Su2002</td>
<td>Microarray analysis of Dclk1-positive intestinal tumor stem cells</td>
<td>Su2025</td>
<td>5*</td>
</tr>
<tr>
<td>Su2003</td>
<td>Nrip2, a novel regulator</td>
<td>Su2026</td>
<td>5*</td>
</tr>
<tr>
<td>Su2004</td>
<td>Enhanced expression of doublecortin-like kinase 1</td>
<td>Su2027</td>
<td>5*</td>
</tr>
<tr>
<td>Su2005</td>
<td>DCLK1 promotes pancreatic cancer cell clonogenicity</td>
<td>Su2028</td>
<td>5*</td>
</tr>
<tr>
<td>Su2006</td>
<td>The DCLK1 Tumor Stem Cell Marker</td>
<td>Su2029</td>
<td>5*</td>
</tr>
<tr>
<td>Su2007</td>
<td>Helicobacter Pylori-induced hypermethylation</td>
<td>Su2030</td>
<td>5*</td>
</tr>
<tr>
<td>Su2008</td>
<td>Association of epithelial-mesenchymal transition</td>
<td>Su2031</td>
<td>5*</td>
</tr>
<tr>
<td>Su2009</td>
<td>HIV infection and domestic smoke exposure</td>
<td>Su2032</td>
<td>5*</td>
</tr>
<tr>
<td>Su2010</td>
<td>The association between peptic ulcer</td>
<td>Su2033</td>
<td>5*</td>
</tr>
<tr>
<td>Su2011</td>
<td>Atoh1 protein expression by TNF-a and the acquisition of malignant potential</td>
<td>Su2034</td>
<td>5*</td>
</tr>
<tr>
<td>Su2012</td>
<td>A First Case Report of Colorectal Cancer</td>
<td>Su2035</td>
<td>5*</td>
</tr>
<tr>
<td>Su2013</td>
<td>Role of inflammation induced by the serine-protease granzyme A</td>
<td>Su2036</td>
<td>5*</td>
</tr>
<tr>
<td>Su2014</td>
<td>Revised Predictive Values for IBD Colitis-associated Neoplasia</td>
<td>Su2037</td>
<td>5*</td>
</tr>
<tr>
<td>Su2015</td>
<td>Identification of colorectal cancer-associated Escherichia coli</td>
<td>Su2038</td>
<td>5*</td>
</tr>
<tr>
<td>Su2016</td>
<td>A novel association of gastrointestinal stromal tumors</td>
<td>Su2039</td>
<td>5*</td>
</tr>
<tr>
<td>Su2017</td>
<td>Matrix metalloproteinase (MMP9) regulates (6*)</td>
<td>Su2040</td>
<td>5*</td>
</tr>
<tr>
<td>Su2018</td>
<td>Macrophage Targeting Contributes to the Inhibitory Effects</td>
<td>Su2041</td>
<td>5*</td>
</tr>
</tbody>
</table>

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding    (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)    (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Su2042 | Corticotropin-releasing factor changes the phenotype...[2*] This study was supported by the Natural Science Foundation of Zhejiang province (LZ12H03001). |
| Su2043 | Responses of the Guinea Pig Enteric Nervous System...[2*] |
| Su2044 | The beneficial effect of partially hydrolyzed guar gum...[2*] |
| Su2045 | Mast Cell CRF1 Mediates Mast Cell Degranulation...[2*] |
| Su2046 | Gut microbiota correlate with...[4*] |
| Su2047 | Fecal and mucosal intestinal microbiota...[4*] |
| Su2048 | PI-IBS patients display a altered ex vivo immune response...[4*] |
| Su2049 | The proteasome system is altered in colonic mucosa...[5*] |
| Su2050 | Supernatants of mucosal biopsies...[5*] |
| Su2051 | Combined polyethylene glycol...[2*] | *Boehringer provided product free Norgine provided product at low cost. |
| Su2052 | Annual costs of care for pediatric irritable bowel syndrome...[2*] |
| Su2053 | Is Cystic Fibrosis Associated with Gastroaresis?...[5*] |
| Su2054 | Yoga Therapy for Children...[4*] |
| Su2055 | Epidemiology of Pediatric Functional Abdominal Pain Disorders...[5*] |
| Su2056 | Effect of octreotide on the colonic motility...[5*] |
| Su2057 | Comparison of Primary Efficacy Endpoints...[4*] |
| Su2058 | When is Pain Improvement Considered Clinically Meaningful?...[4*] |
| Su2059 | A New Combined Clinical Endpoint for Clinical Trials...[4*] |
| Su2060 | Impact of laparoscopic antireflux surgery on belching...[4*] |
| Su2061 | Utilising high-resolution colonic manometry...[2*] |
| Su2062 | Current symptoms and quality of life in patients...[5*] |

| Su2063 | Pediatric Achalasia: diagnosis, management...[5*] |
| Su2064 | Brain processing of rectal sensation...[5*] |
| Su2065 | Antimicrobial peptide cathelicidin inhibits obesity...[2*] | *(6) |
| Su2066 | Immune neutralization of Gastric Inhibitory Polypeptide...[4*] |
| Su2067 | A Pilot Pharmacogenomic Study of the Effects of Exenatide...[2*] |
| Su2068 | I6S Gene Sequencing Reveals a Unique Bacterial Signature...[2*] |
| Su2069 | Association of tumor Fusobacterium status...[5*] |
| Su2070 | Prevalence and predictors of patient no-shows...[5*] |
| Su2071 | Race and Ethnicity Predict Lack of Physician Recommendation...[2*] |
| Su2072 | Cost and Availability of Gluten-Free Foods in the UK...[5*] |
| Su2073 | Metformin, Insulin therapy and risk of colorectal neoplasia...[2*] |
| Su2074 | Hospital Inpatient Population Diversity...[5*] |
| Su2075 | Resource utilization for common inpatient GI conditions...[5*] |
| Su2076 | Health Disparity: Assessing Effectiveness of Bilingual Patient Navigators...[4*] |
| Su2077 | Analysis of Factors Predictive of Postoperative Complications...[5*] |
| Su2078 | Adenoma Prevalence and Distribution among U.S. Puerto Ricans...[6*] |
| Su2079 | Impact of Race, Income and Health Insurance on Healthcare Outcomes...[5*] |
| Su2080 | Colecystectomy in Adults with Ulcerative Colitis...[5*] |
| Su2081 | Surgical Management of Hospitalized Adults with Crohn’s Disease...[5*] |
| Su2082 | Nationwide Disparities in the Inpatient Utilization of Colonic Stents...[5*] |

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIB, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CFTA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1087. Are gastroenterologists perceived as "scope monkeys"? (5*)
Mo1088. Evaluation of symptomatic burden of ulcerative colitis (3*) Merck Sharp & Dohme de España
Mo1089. Social Media Ethnography of GERD Patients (4*)
Mo1090. Impact of multidisciplinary team discussion (5*)
Mo1091. Utility of abdominal CT scanning (4*)
Mo1092. Reporting Quality Indicators During Colonoscopy (5*)
Mo1093. A Review of Preoperative Imaging in Appendectomy (5*)
Mo1094. Reducing Hospital Admissions for Paracentesis (5*)
Mo1095. Reasons for Lack of Follow-up Colonoscopy (2*)
Mo1096. Bridges To Excellence (BTE) Quality Indicators (5*)
Mo1097. Pre-transplant Fundoplication is Non-Inferior (5*)
Mo1098. Decreased Esophageal Bolus Clearance (5*)
Mo1099. The Impact of Gastroesophageal Reflex (5*)
Mo1100. Increased Incidence of Barrett’s Esophagus (5*)
Mo1101. Cough-Specific Quality of Life (5*)
Mo1102. Bioelectric impedance and Anthropometric measurements (5*)
Mo1103. Quality of life, patient satisfaction and disease burden in patients (4*)
Mo1104. Safety of an Intentionally Displaced Upper Esophageal (3*) Somna Therapeutics, LLC.
Mo1105. Proton-pump inhibitors: Do these drugs improve (5*)
Mo1106. Detection of laryngo-pharyngeal reflux (5*)
Mo1107. Differences of LES Impedance Planimetry (5*)
Mo1108. Patients with refractory reflux symptoms (2*)
Mo1109. Acid and weakly acidic reflux as a cause (2*)
Mo1110. pH of the pharynx is associated with (2*)
Mo1111. Night time acid clearance is related to (5*)
Mo1112. New lesion of the stomach, black spots (4*)
Mo1113. Relevance of mixed reflux and weak peristalsis (5*)
Mo1114. Increased frequency of swallows during 24 hours (5*)
Mo1115. Salivary Pepsin Concentrations are Higher (4*) Restech device and peptests were donated by the mirs.
Mo1116. Clinical And Impedance-pH Patterns Predict (5*)
Mo1117. Patients with Non-Acid Reflux Disease (5*)
Mo1118. Lung Disease Severity in Idiopathic Pulmonary Fibrosis (5*)
Mo1119. Detection of reflux mechanisms in PPI non-responder (2*)
Mo1120. The first 30-min basal impedance levels (5*)
Mo1121. Bolus contact time differences in patients (5*)
Mo1122. Prevalence, Characteristics and Treatment Outcomes (4*)
Mo1123. Oesophageal intraluminal baseline impedance levels in patients (7*)
Mo1124. Gastroesophageal Reflux Disease (5*)
Mo1125. Quantitative assessment of acid reflux (5*)
Mo1126. GERD-related Symptom Recurrence (5*)
Mo1127. Role of Distal Esophageal Acidification (2*)
Mo1128. Are Baseline Impedance Levels Assessed (5*)
Mo1129. Distributed Acoustic Catheter for Real-Time (2*)[(1]
Mo1130. The association between objective tongue color (2*)[(4]
Mo1131. The 48-Hour wireless pH capsule (5*)
Mo1132. Intraluminal impedance versus mucosal impedance testing (5*)
Mo1133. Narrow-band imaging demonstrates abnormalities in NERD (5*)
Mo1134. Nocturnal GERD in pregnancy (4*)
Mo1135. Gastrin 17 As Non-Invasive Marker (5*)
Mo1136. The Effect of Swallowing on Esophageal Basal Impedance (5*)
Mo1137. Use of a Sleep Positioning Device (5*) Amenity Health provided the Medcline Reflux System to subjects at no charge.
Mo1138. The Pharmacokinetics and Pharmacodynamics of (3*) Takeda Development Center Americas, Inc.
Mo1139. Modulation of pulse parameters for electrical stimulation (5*)
Mo1140. Clinical Efficacy Of Diaphragmatic Breathing (5*)
Mo1141. The feasibility and acceptability of esophageal-directed (4*)
Mo1142. Efficacy of surgical spinal correction in patients (5*)
Mo1143. Being a CYP2C19 rapid metabolizer is a risk factor (5*)
Mo1144. Proton Pump Inhibitors Alter Specific Taxis (5*)
Mo1145. Use of proton pump inhibitors is associated with (5*)
Mo1146. Localization of a novel potassium competitive acid blocker (3*) Takeda Pharmaceutical Company Limited
Mo1147. A crossover study to evaluate the acid-inhibitory effect (3*)
Mo1148. Effects of Long-Term Proton Pump Inhibitor Use (3*) This study was funded by AstraZeneca.
Mo1149. Concomitant Administration of H2 Receptor Antagonist (5*)
Mo1150. Double action alginates-antacid tablets (3*) Sponsor: Reckitt Benckiser Healthcare (UK) Limited
Mo1151. Alginates-antacid chewable tablets (3*) This study was funded in full by Reckitt Benckiser.

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NHLBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. AFAA, CFTA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds
(2) = Government (e.g. NBI, CDC, Health Ministry, etc.)
(3) = Industry or Commercial Entity
(4) = Institutional Funds
(5) = No Study Funding
(6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)
(7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1220. . . . . Faecal microbiota transplantation via nasogastric... (5*)
Mo1221. . . . . Comparative assessments of FF-06438179... (4*) Pfizer Inc.
Mo1222. . . . . Usefulness of Laser Doppler Perfusion Imaging... (5*)
Mo1223. . . . . Lower expression of PPARy in AVM tissue... (4*)
Mo1224. . . . . Contrasting Regional Availability of Different... (2*)
Mo1225. . . . . Factors Associated with C. difficile... (5*)
Mo1226. . . . . MRI Scans Should be Used to Monitor... (4*)
Mo1227. . . . . Cathelicidin mimic Ceragenin CSA13... (2*) (6)
Mo1228. . . . . Deflating the Pipes... (5*)
Mo1229. . . . . Treating Small Bowel Obstruction... (1*)
Mo1230. . . . . Contrast-enhanced ultrasonography... (5*)
Mo1231. . . . . Attenuation of intestinal inflammation... (6*) (2)
Mo1232. . . . . Development of an enhanced nutritional therapy... (6*) (2)
Mo1233. . . . . Pharmacologic Evaluation of Clinical Neutral Endopeptidase... (6*)
Mo1234. . . . . Two case reports of toxic megacolon... (5*)
Mo1235. . . . . A Rare Case of Enterocolic gallinatum... (5*)
Mo1236. . . . . Early rebleeding and mortality... (5*)
Mo1237. . . . . Patient-Reported Health-Related Quality of Life Outcomes... (2*)
Mo1238. . . . . Thromboelastography for Predicting Differences... (5*)
Mo1239. . . . . Inpatient-Onset Primary Esophageal Variceal Hemorrhage... (6*)
Mo1240. . . . . Spleen and Liver Volumes are Strongly Correlated... (2*)
Mo1241. . . . . Survival Analysis of antibiotics... (5*)
Mo1242. . . . . A non-invasive predictive score... (5*)
Mo1243. . . . . Colonoscopy with polypectomy is associated with... (5*)
Mo1244. . . . . New organ allocation score predicting... (5*)
Mo1245. . . . . Risk factors associated with overall and bleeding-related... (5*)
Mo1246. . . . . Seasonal variations among hospitalizations related to... (2*)
Mo1247. . . . . Neutrophil and monocyte activity in stable cirrhosis... (5*)
Mo1248. . . . . Psychosocial Interventions to Achieve Abstinence... (5*)
Mo1249. . . . . The healing of colocutaneous fistulas and diclofenac overdose... (2*)
Mo1250. . . . . Portal triad clamping in rats, BPC 157... (2*)
Mo1251. . . . . Effect of rifaximin therapy on the plasma level... (5*)
Mo1252. . . . . Most liver related deaths in India are caused by alcohol... (5*)
Mo1253. . . . . Should patients with hepatocellular carcinoma... (5*)
Mo1254. . . . . Alcoholic Hepatitis – a Risk Factor... (5*)
Mo1255. . . . . Cryptococcal Meningitis and Cirrhosis... (5*)
Mo1256. . . . . First steps towards understanding the dynamic evolution... (5*)
Mo1257. . . . . The microbial basis of rifaximin efficacy... (5*)
Mo1258. . . . . Risk Factors of Variceal and Non-variceal... (5*)
Mo1259. . . . . Olfactory function is affected in patients with cirrhosis... (5*)
Mo1260. . . . . Comparison of Symptoms, Health Care Utilization... (3*) Funding for data analyses provided by Salix Pharmaceuticals, Inc.
Mo1261. . . . . Characterizing the Effect of Rifaximin... (3*) Research funded by Salix Pharmaceuticals, Inc.
Mo1262. . . . . Effects of Baseline Abdominal Pain... (3*) Sucampo Pharma Americas, LLC, Bethesda, MD, and Takeda Pharmaceuticals International, Deerfield, IL.
Mo1263. . . . . Anxiety and depression increase in a step-wise fashion... (5*)
Mo1264. . . . . A randomized, controlled trial comparing a diet... (2*) (4)
Mo1265. . . . . Randomized, Double-blind, Cross-over Study... (2*)
Mo1266. . . . . Reliability and Agreement of the Seven Category... (2*)
Mo1267. . . . . Rifaximin for IBS-D... (3*) Salix Pharmaceuticals, Inc.
Mo1268. . . . . Characterization of Stool Microbiota... (3*) Salix Pharmaceuticals, Inc.
Mo1269. . . . . Enduring Effects Following a Course of Rifaximin Therapy... (3*) Research funded by Salix Pharmaceuticals, Inc.
Mo1270. . . . . Low sense of coherence is associated with reduced... (2*) (4)
Mo1271. . . . . Age Moderates the Relationship... (2*)
Mo1272. . . . . Effects of age and gender on disease-specific Quality of Life... (5*)
Mo1273. . . . . The association of Early Adverse Life Events... (2*)
Mo1274. . . . . Disease Relevant Components of Mindfulness... (2*)
Mo1275. . . . . Safety and Tolerability of Rifaximin... (3*) Study funded by Salix Pharmaceuticals, Inc.
Mo1276. . . . . Abuse Histories Predict Greater Functional GI... (2*)
Mo1277. . . . . Clinical Factors Associated with Opioid Prescription Use... (2*)
Mo1278. . . . . Review of Systems and Medication Allergies... (2*)
Mo1279. . . . . Durability of Benefit in IBS-D Patients... (3*) Salix Pharmaceuticals, Inc.
Mo1280. . . . . Effect of Ramosetron in Female Patients... (3*) (4) This study was funded by Astellas Pharma Inc.
Mo1281. . . . . Optimal Dose of Ramosetron in Female Patients... (3*) (4) This study was funded by Astellas Pharma Inc.
Mo1282. . . . . Attachment styles in patients with Irritable Bowel... (5*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1283. . . . . . Fecal Short Chain Fatty Acids...\(4^*)
Mo1284. . . . . . Real-world effectiveness of exposure-based cognitive behavioral...\(1^*)
Mo1285. . . . . . Change of appetite in patients...\(5^*)
Mo1286. . . . . . Sleep disturbances and functional gastrointestinal disorders...\(5^*)
Mo1288. . . . . . Internal consistency and test-retest reliability...\(2^*)
Mo1289. . . . . . Are antibiotics a risk factor for Irritable Bowel Syndrome...\(4^*)(1)
Mo1290. . . . . . IBgard®, a novel targeted delivery system...\(3^*) IM HealthScience™ LLC.
Mo1291. . . . . . Improvements in IBS-Related Quality of Life...\(3^*) Salix Pharmaceuticals, Inc.
Mo1292. . . . . . Low FODMAP diet for Irritable Bowel Syndrome...\(5^*)
Mo1293. . . . . . Adverse Childhood Experiences are Associated with...\(2^*)
Mo1294. . . . . . Body Dissatisfaction and Disordered Eating...\(5^*)
Mo1295. . . . . . Histamine intolerance syndrome is a differential diagnosis...\(5^*)
Mo1296. . . . . . Proton pump inhibitors (PPIs) are associated with the onset...\(3^*) This study was funded by Alfa Wasserman SA de CV, Mexico.
Mo1297. . . . . . Mexican patients do not understand the term...\(5^*)
Mo1298. . . . . . Validation of KEMH Fecograph...\(5^*)
Mo1299. . . . . . Six versus twelve sessions of hypnotherapy...\(2^*)
Mo1300. . . . . . Gallbladder emptying in relation to gastric emptying...\(2^*)
Mo1301. . . . . . Wireless motility capsule (SmartPill)...\(4^*)(1)
Mo1302. . . . . . Contribution of dietary factors to the risk...\(2^*)
Mo1303. . . . . . Inflammation and impaired motility...\(5^*)
Mo1304. . . . . . The Effect of YH12852, Novel 5-HT\(_4\) partial agonist...\(5^*)
Mo1306. . . . . . Structural and functional abnormalities...\(3^*) \(2^*) Covidien
Mo1307. . . . . . Single-visit measures of postprandial pan-intestinal...\(4^*)
Mo1308. . . . . . Effects and mechanisms of the electroacupuncture...\(5^*)
Mo1309. . . . . . hyperglycemia-induced small intestinal dyrythmias...\(2^*)
Mo1310. . . . . . High fat-diet induces slow wave dyrythmia...\(4^*) Veterans Research and Education Foundation, VA Medical Center
Mo1311. . . . . . Co-transmission by nirtic oxide...\(4^*)
Mo1312. . . . . . Transient receptor potential ankyrin I...\(4^*)(3) Tsumura & Co.
Mo1313. . . . . . A Rapid Initial Lag Phase of Gastric Emptying...\(5^*)
Mo1314. . . . . . Resolution of GERD Symptoms...\(5^*)
Mo1315. . . . . . Adherence to vitamin D screening...\(5^*)
Mo1316. . . . . . Effect of intragastric injection of Botulinum Toxin A...\(5^*)
Mo1317. . . . . . Static and dynamic measurements of C-peptide...\(6^*)
Mo1318. . . . . . CD24 polymorphisms are associated with obesity risk...\(4^*)
Mo1319. . . . . . Obesity, waist-hip-ratio, diet, and physical activity...\(7^*) \(2^*)
Mo1320. . . . . . Prevalence of Extrahepatic Complications...\(5^*)
Mo1321. . . . . . Bias towards Big: Patients Preferring to be Obese...\(5^*)
Mo1322. . . . . . Age-Specific and Race-Specific Disparities...\(5^*)
Mo1323. . . . . . High Protein Diet Improves Body Mass Index...\(2^*)
Mo1324. . . . . . Body Mass Index association with...\(5^*)
Mo1325. . . . . . Analysis of Insulin Resistance, Body Composition...\(5^*)
Mo1326. . . . . . Increased risk of functional gastrointestinal disorders...\(5^*)
Mo1327. . . . . . Does morbid obesity protect from Diabetes?...\(5^*)
Mo1328. . . . . . Role of Endoscopy in asymptomatic adult obese patients...\(5^*)
Mo1329. . . . . . Obesity Increases Risk of Small Intestinal Bacterial...\(5^*)
Mo1330. . . . . . A Daily 5000IU vs. Weekly 50,000IU Vitamin D...\(5^*)
Mo1331. . . . . . Proton Pump Inhibitor Use is Associated with...\(7^*)
Mo1332. . . . . . Upper gastrointestinal system endoscopic findings in obese patients...\(4^*)
Mo1333. . . . . . Adiposity is associated with alterations...\(2^*)
Mo1334. . . . . . Comparative study to assess the outcome...\(5^*)
Mo1335. . . . . . Impact of characteristics of acute fluid collections...\(5^*)
Mo1336. . . . . . Early versus Delayed initiation...\(5^*)
Mo1337. . . . . . The metabolomics profile in acute pancreatitis...\(2^*)
Mo1338. . . . . . Respiratory rate: the single important factor of SIRS...\(5^*)
Mo1339. . . . . . Nation-Wide Multicenter Prospective Validation...\(5^*)
Mo1340. . . . . . Impact of the site of necrosis...\(5^*)
Mo1341. . . . . . Differences in Severity and Outcomes...\(5^*)
Mo1342. . . . . . Use of streptokinase for enhancement of percutaneous...\(4^*)
Mo1343. . . . . . BISAP-0 and APACHE-0...\(5^*)
Mo1344. . . . . . Continuous regional arterial infusion of protease inhibitors...\(4^*)
Mo1345. . . . . . Oral feeding versus nasogastric feeding...\(5^*)
Mo1346. . . . . . Peripancreatic necrosis: Prevalence and clinical outcomes...\(5^*)
Mo1347. . . . . . Soluble urokinase-type plasminogen activator receptor...\(2^*)
Mo1348. . . . . . Obesity as a predictor of severity...\(5^*)

Abstract Funding Source Key
* = Primary Source
\(1^*) = Clinical Practice Funds \(2^*) = Government (e.g. NHI, CDC, Health Ministry, etc.) \(3^*) = Industry or Commercial Entity \(4^*) = Institutional Funds
\(5^*) = No Study Funding \(6^*) = Philanthropic Organization (e.g. ALF, CFTA, etc.) \(7^*) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1349. Validation of Japanese Severity Score. (2*)
Mo1350. Severity and natural history of acute pancreatitis. (4*) Dr.Dhiraj Yadav is a consultant for AbbVie.
Mo1351. Systemic levels of soluble urokinase-type. (4*)
Mo1352. Efficacy of Conservative and Minimally Invasive Approach. (5*)
Mo1353. Diagnostic Yield of Performing EUS. (5*)
Mo1354. Age Adjusted Charlson Comorbidity Index. (5*)
Mo1355. Factors Affecting Cholecystectomy. (5*)
Mo1356. Are the current diagnostic criteria for acute cholangitis? (5*)
Mo1357. Endocrine dysfunction in patients with acute pancreatitis. (5*)
Mo1358. Patients with repeat attacks of acute pancreatitis. (5*)
Mo1359. Early predictors of severe pancreatitis in children. (5*)
Mo1360. Low Molecular Weight Heparin Treatment. (5*)
Mo1361. Prevalence and in-hospital mortality trends. (5*)
Mo1362. Multidisciplinary approach to disconnected pancreatic duct. (5*)
Mo1363. Role of early prediction of pancreatic necrosis. (2*)
Mo1364. Inpatient burden of acute pancreatitis. (5*)
Mo1365. Impact of simvastatin on risk of recurrent acute pancreatitis. (4*)
Mo1366. C Reactive Protein - A rapid and cost effective marker. (1*)
Mo1367. Splanchnic Vein Thrombosis in Acute Pancreatitis. (5*)
Mo1368. Inflammation via the Fractalkine (CX3CL1)/CX3CR1. (5*)
Mo1369. TLR3 Preconditioning Enhances the Therapeutic Efficacy. (2*)
Mo1370. Anti-inflammatory properties of the neuropeptide. (2*) (4)
Mo1685. Role of EBI2 and Oxyesters. (2*) (6) Novartis supported the project by supplying some of the mice used in the experiments and by providing some chemicals. No financial support was provided by Novartis.
Mo1686. DSP-8250, a full human anti-CD81 antibody. (3*) (4)
Mo1687. Oral delivery of a new class of non-antibody protein. (2*)
Mo1688. Human CD4 T Cell-Mediated cytokine. (2*)
Mo1689. Nicotine significantly affects the expression. (5*)
Mo1690. Serotonin/5-HT3 Receptor and Substance P/NK1 Receptor. (5*)
Mo1691. Lanthionine synthetase C-like Receptor 2 (LANCL2). (2*)
Mo1692. Vascular endothelial transient receptor. (5*)
Mo1693. Activation of Bone Marrow-derived. (4*)
Mo1694. Potential role of palmitoleate. (4*) (2)
Mo1695. Influence of gastrointestinal microbiota. (2*)
Mo1696. CX3CL1 - CX3CR1 in Acute Colitis. (6*)
Mo1697. Male-dependent promotion of colitis. (2*)
Mo1698. Genetic deletion of the IL-13 decoy receptor. (2*) This research was made possible through the National Institutes of Health (NIH) Medical Research Scholars Program, a public-private partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from Pfizer Inc, The Doris Duke Charitable Foundation, The Newport Foundation, The American Association for Dental Research, The Howard Hughes Medical Institute, and the Colgate-Palmolive Company, as well as other private donors.
Mo1699. Denosumab: a monoclonal antibody. (4*)
Mo1700. Targeted Topical Therapy to Treat Inflammatory Bowel Disease. (6*) (4)
Mo1701. Selective Janus Kinase 1 inhibitor. (3*) GlaxoSmithKline
Mo1702. Wound integrity and collagen expression. (3*) UCB pharmaceutical provided funding for this study
Mo1703. Indigo Naturalis ameliorates murine. (2*)
Mo1704. Is Eph-ephrin signaling beneficial. (4*)
Mo1705. All-trans retinoic acid ameliorates. (2*)
Mo1706. Local application of adipose-derived mesenchymal. (4*)
Mo1707. Serial treatment with anti-TNF Al. (5*) AbbVie
Mo1708. Improved Tryptophan Metabolism. (3*) Entera Health Inc.
Mo1709. Abnormal Hedgehog signaling. (5*)
Mo1710. Regulation of Smad7 Translation. (5*)
Mo1711. Interleukin 35 and 37 Intestinal Expression. (4*)
Mo1712. Role of Interleukin 27 (IL-27). (4*)
Mo1713. Binding of infliximab to human serum exosomes. (5*)
Mo1714. Analysis of the protease MT1-MMP. (5*)
Mo1715. The effect of lymphocyte function. (2*)
Mo1716. IL-1 receptor antagonist (Anakinra) restores. (4*)
Mo1717. Expression and localization of NLRP3. (4*)
Mo1718. CD11c positive dendritic cells. (6*)
Mo1719. Epithelial NF-kB activation via TNF signaling. (2*) (6)
Mo1720. IFN-γ Counteracts the Angiogenic Switch. (2*)
Mo1721. Methylation and Expression of the Genes. (4*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CFFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1722. . . . . The role of Interleukin 36..(5*)
Mo1723. . . . . Role of CCL20-CCR6 axis and MNP9..(4*)
Mo1724. . . . . Interleukin-17A Homodimer Reduces Pro-Inflammatory..(5*)
Mo1725. . . . . TL1A Mediated Activation of Early Response Genes..(2*)[4]
Mo1726. . . . . IL12B, susceptibility loci..(2*)
Mo1727. . . . . Drug therapies in Ulcerative Colitis..(5*)
Mo1728. . . . . Cytokine and microRNA expression..(5*)
Mo1729. . . . . Mucosal gene expression patterns..(2*)
Mo1730. . . . . The jasmonate analogue 2-hydroxyethyl..(5*)
Mo1731. . . . . Serum and Mucosal IgG4 is Closely Associated With..(4*)
Mo1732. . . . . Detection of Active Cathepsin S..(2*)[7](6)
Mo1733. . . . . Increased ileal and colonic concentrations of Th1 and Th17..(4*)
Mo1734. . . . . Serum Fatty Acids Are Correlated with..(2*)
Mo1735. . . . . Regulation of TREM-1 and TREM-2 protein..(4*)
Mo1736. . . . . The effect of the electronic cigarette..(4*)
Mo1737. . . . . Granulo-monocytes Apheresis Induce TGFβ1 Modulation..(5*)
Mo1738. . . . . The intestinal commensal Bifidobacterium infantis..(2*)
Mo1739. . . . . LPS stimulated whole blood cytokine production..(5*)
Mo1740. . . . . Mucosal Chitinase 3-like 1 (CHI3L1) secretion..(4*)[3] This work was partially supported by Immune pharma.
Mo1741. . . . . In Ulcerative Colitis Lamina Propria CD4+LAP+ Fospx3- regulatory..(2*)
Mo1742. . . . . New insights in iron homeostasis..(4*)
Mo1743. . . . . Genotyping of NUDT15 R139C could be a companion..(4*)
Mo1744. . . . . Ulcerative colitis patients with endoscopic healing..(2*)[4]
Mo1745. . . . . The development of antibodies to infliximab..(5*) Prometheus laboratories performed the genotyping of the HLA-DRB1 allele group in our samples. They were not involved in the processing and the statistical analysis of the results or the conclusions in this abstract.
Mo1746. . . . . Human-leukocyte antigen type is associated with..(5*) Prometheus laboratories performed the genotyping of the HLA-DRB1 allele group. They were not involved in the processing and the statistical analysis of the results or the conclusions in this abstract.
Mo1747. . . . . Adipose Tissue from Visceral Fat..(5*)
Mo1748. . . . . DNA methylation profiles of CD4+ effector memory T-cells..(4*)
Mo1749. . . . . Epigenetic regulation in inflammatory bowel disease..(6*)
Mo1750. . . . . Genetic Associations with Preferential 6TGN Metabolizers..(5*)
Mo1751. . . . . Relating genetic variants in IBD..(5*)
Mo1752. . . . . miR-424 may regulate transcripts..(6*)
Mo1753. . . . . Epigenetic Mechanisms of AIEC-Receptor CEACAM6 Regulation..(4*)
Mo1754. . . . . Early life environment interacts with genetic risk..(2*)
Mo1755. . . . . Myeloid differentiation factor 88..(2*)[6]
Mo1756. . . . . Genetic deletion of tissue inhibitor..(2*)[4]
Mo1757. . . . . Evidence for a Role of Superantigens..(6*)
Mo1758. . . . . Impact of intestinal inflammation..(4*)
Mo1759. . . . . Reciprocal IL-22 Expression Masks IL-17 Activities..(5*)
Mo1760. . . . . Pharmacology of the anti-CD40 agonist acute colitis model..(3*) AbbVie Bioresearch Center, 100 Research Dr. Worcester MA 01605
Mo1761. . . . . Mesenteric fat cells induce proliferation..(2*)
Mo1762. . . . . Soft ROCK inhibition prevents intestinal fibrosis..(4*)
Mo1763. . . . . Increased Matrix stiffness Modulates MicroRNA..(2*)
Mo1764. . . . . The expression of TL1A/TNFSF15 is highly upregulated..(5*)
Mo1765. . . . . The role of NADPH oxidase (NOX) 4..(2*)
Mo1766. . . . . Mucus produced by stem cell derived human colonoids..(2*)
Mo1767. . . . . CD24 plays a role..(4*)
Mo1768. . . . . Western Diet Reduces Short-Chain Fatty Acids..(4*)
Mo1769. . . . . The susceptibility to intestinal inflammation..(2*)[4](6)
Mo1770. . . . . GipA factor supports Crohn's disease-associated..(5*)
Mo1771. . . . . Microbiota regulate Lung dendritic cells..(4*)[2][6]
Mo1772. . . . . DUOX2 - A novel player in IBD..(6*)
Mo1773. . . . . IL-10R Signaling Restricts the Expansion..(6*)[4]
Mo1774. . . . . Prenatal antibiotic treatment increases..(4*)
Mo1775. . . . . Colonic microbiome and barrier dysfunction..(2*)
Mo1776. . . . . Increased severity of DSS-induced colitis..(6*)[2]
Mo1777. . . . . Involvement of type VI secretion systems..(4*)
Mo1778. . . . . Transient activation of mucosal immune responses..(2*)[6]
Mo1779. . . . . The Impact of a "Westernized" Diet..(2*)
Mo1780. . . . . Fecal mirnas: An indicator of Intestinal Microbiota..(2*)[6]
Mo1781. . . . . Crohn's disease-associated adherent-invasive Escherichia coli..(4*)
Mo1782. . . . . Presence of genotypes of Bacteroidetes..(5*)
Mo1783. . . . . Fecalibacterium prausnitzii inhibiting..(2*)
Mo1784. . . . . Inflammatory macrophages response to stimulation..(5*)

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1785. Intestinal epithelial cells contribute...(2*)
Mo1786. Different strains of H. pylori...(2*)
Mo1787. Soluble plantain (banana) fibre inhibits the epithelial IL-8...(7*)](3) Grant/research support from Provexis plc (UK) and Bo and Vera Ax:son Johnson Foundation for Nature Medicine Limited (IoM).
Mo1788. Targeting the gut microbiome with antibiotics...(2*)
Mo1789. Colonization with non-pathogenic Escherichia coli...(4*)
Mo1790. Butyrate Induces Intestinal Epithelial Cell...(2*) Supported by grants from the Natural Science Foundation of China (81270470, 81470822).
Mo1791. Ulcerative Colitis-associated Escherichia coli...(4*)
Mo1792. Alterations in gut microbiota composition...(2*)
Mo1793. Gut microbiome composition change in Crohn’s...(4*)
Mo1794. Predominant intestinal microbiota...(4*)
Mo1795. Environmental and demographic factors...(6*)
Mo1796. The Gut Microbiome Differentiates Clinical Phenotypes...(3*) Janssen Research & Development
Mo1797. Disease specific differences in intestinal microbiota...(5*)
Mo1798. Sampling of the Mucosal Microbiota...(2*)
Mo1799. Increased Fecal Water Cytotoxicity...(4*)
Mo1800. Colonic Luminal Compounds Do Not Affect...(4*)
Mo1801. Compositonally and Functionally Distinct Gut...(6*)
Mo1802. Intestinal dysbiosis in collagenous colitis...(4*)
Mo1803. Stressor-induced Dysbiosis is Associated with...(2*)
Mo1804. Composition and stability of the mucosal-associated...(2*)](3) Valio Ltd.
Mo1805. Untargeted metabolomics reveals disruption...(4*)
Mo1806. Helminth-induced alterations in the gut microbiota...(2*)
Mo1807. Common Pharmaceuticals Shift in Gut Microbiome Composition...(3*)
Mo1808. Post-Partum Antibiotic Treatment...(2*)](3) Our study is funded in part by the Netherlands Enterprise Agency (Agentschap NL, FND-06015) and Nutricia Medical Devices, Zoetermeer, the Netherlands.
Mo1809. Variations in Longitudinal Microbiome...(4*)
Mo1810. Gut Microbiome Characteristics of IBD Patients...(4*)
Mo1811. Clinical remission induced by exclusive enteral nutrition...(7*)](2)
Mo1812. Diversity of duodenal and rectal microbiota...(2*)
Mo1813. Antibiotics provoke a dysbiosis - isotretinoin not...(3*)
Mo1814. The N-acyl-homoserine lactone 3-oxo-C12...(4*)
Mo1815. A simple biomarker for IBD associated dysbiosis...(4*)
Mo1816. The impact of NOD2 variants...(6*)](6)
Mo1817. Warfarin induces intestinal dysbiosis...(4*)](2)
Mo1818. Effect of aging on the fecal microbiome...(4*)
Mo1819. Activation of autophagy by Crohn’s disease-associated E. coli...(2*)](4)
Mo1820. Activation of the GCN2/eIF2alpha/ATF4 signaling...(4*)](7)
Mo1821. TRIF is required for effective immunological memory...(2*)
Mo1822. Dietary Wheat Alpha-Amylase-Trypsin Inhibitors...(4*)
Mo1823. mIR-S11-3p, embedded in the macrophage mannose...(2*)](7)
Mo1824. The interaction of enteric bacterial effectors...(2*)
Mo1825. Impaired fibrolysis contributes to the pathogenesis...(3*) American Heart Association
Mo1826. HDAC 5 as a Promising Target...(4*)](2)
Mo1827. Reduced Intestinal Leukocyte Exit...(2*)](7)
Mo1828. Mucosal response to fungi...(6*)
Mo1829. Retinoic acid primed dendritic cells...(2*)
Mo1830. Control of Enterococcus faecalis translocation...(5*)
Mo1831. In-vivo animal model to study antimicrobial therapy...(4*)
Mo1832. Human alpha-Defensin 6 regulated by the cooperation...(2*)
Mo1833. NOD2 downregulates colonic inflammation...(2*)
Mo1834. Investigation of slow cycling stem cells...(4*)
Mo1835. A leaky colonic vascular barrier...(6*)
Mo1836. Viral products elicit different phenotypes...(2*)](6)
Mo1837. Inhibition of microRNA-29a in human bone marrow...(7*)
Mo1838. Effect of Chang medium on proliferation...(2*)
Mo1839. HDAC 5 as a Promising Target...(4*)](2)
Mo1840. Fecal Microbiota Transplantation...(5*)
Mo1841. EPEC affects the Crumbs polarity complex...(2*)
Mo1842. Saccharomyces boulardii strain CNCM I-745...(2*)](3) BioCedex SA
Mo1843. Effect of Saccharomyces boulardii strain CNCM I-745...(2*)](3) BIOCODEX SA
Mo1844. Effect of fdecacin on susceptibility...(3*) Cubist Pharmaceuticals
Mo1845. Is Colonization with Non-Toxigenic Clostridium Difficile...(5*)
Mo1846. Inhibition of growth of Clostridium difficile...(5*)
Mo1847. The association between Vitamin D...(5*)
Mo1848. Factors predicting development of severe-complicated...(5*)

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Mo1923. Upregulation and the regulation of esophageal...[4*]
Mo1924. Inspiratory esophagogastric junction...[2*]
Mo1925. Estrogen enhances esophageal barrier function...[5*]
Mo1926. Risk for Colorectal Neoplasm in Patients...[5*]
Mo1927. Risk for Colorectal Neoplasia after Initial Colonoscopy...[5*]
Mo1928. Improving participation rates in community-based...[6*]
Mo1929. Comparison of one-day and two-day sampling...[2*]
Mo1930. Post Colonoscopy Colorectal Cancer...[5*]
Mo1931. Comparison of Methylated SEPT9...[2*]
Mo1932. Implementation of an organized, safety-net...[2*]
Mo1933. Prospective Evaluation of the NCI Colorectal Cancer Risk...[4*]
Mo1934. What is the Optimal Use of Total Colonoscopy...[2*]
Mo1935. A novel urine-based metabolomics screening test...[2*]
Mo1936. Characteristics of colorectal tumours...[5*]
Mo1937. Chemerin as a risk factor for human colorectal adenoma...[5*]
Mo1938. The GTA-446 Blood Test...[3*][2*] Phenomenome Discoveries, Inc. funded part of the study.
Mo1939. Performance of a blood methylated mutitarget DNA test...[2*][4*]
Mo1940. Prevalence and risk factors of colonic adenomas...[6*]
Mo1941. Test Performance Characteristics...[2*][3*] Exact Sciences
Mo1942. Predictive Factors of High-risk Adenomas...[2*]
Mo1943. Comparison of a methylated two-gene...[2*][3*][4*] Clinical Genomics
Mo1944. Comparison Between One-Day and Two-Day Sampling...[5*]
Mo1945. Balloon-Assisted Colonoscopy...[3*] The study was supported by SMART Medical Systems Ltd.
Mo1946. Bowel Cancer Screening in Norway...[2*]
Mo1947. Detection of variable methylation patterns...[3*][2*] Clinical Genomics Technologies Pty. Ltd., North Ryde, Sydney, NSW, Australia
Mo1948. Fecal Immunochemical Testing...[5*]
Mo1949. Patterns of Use of CT Colonography...[6*][4*]
Mo1950. Comparison of One versus Two Fecal Immunochemical Tests...[5*]
Mo1951. Rate of detection of Serrated lesions...[5*]
Mo1952. Lower Risk of high risk adenoma (HRA) and colorectal...[5*]
Mo1953. "SCORE" for cardiovascular risk...[1*]
Mo1954. Cost-effectiveness of Organized Programs...[2*]
Mo1955. A significant proportion of patients still require...[5*]
Mo1956. Stage and Site Specific Sensitivity...[2*]
Mo1957. Evaluation of the Performance Characteristics...[5*]
Mo1958. Identifying Who Can Best Assess Barriers...[6*][2*][4*]
Mo1959. Predictors of Primary Care Provider Adoption...[6*][2*][4*]
Mo1960. Evaluation of the "Health Index Equation"...[5*]
Mo1961. Evaluation of the quality of colonoscopy reporting...[5*]
Mo1962. Post-market analysis of the use and effectiveness of GTA-446...[3*]
Mo1963. Use of Integrin Alpha 6 Subunits...[2*]
Mo1964. A cluster randomized trial of directly mailed gFOBT kits...[2*]
Mo1965. Current Colorectal Cancer (CRC) Site Specific Distribution...[4*]
Mo1966. Colorectal Cancer Screening among Asian Subgroups...[2*]
Mo1967. Prediction Score for Risk of Adenoma...[5*]
Mo1968. Trends and Practices of Colorectal Cancer Screening...[7*]
Mo1969. The characteristics of advanced colorectal neoplasias...[2*]
Mo1970. Colorectal Cancer Screening (CRCs) Legislation...[5*]
Mo1971. A Decade of Improved Access to Screening...[5*]
Mo1972. Barriers to Colonoscopy Screening...[6*]
Mo1973. Immunohistochemical Markers Differentiating...[2*]
Mo1974. Performing Against the Benchmark...[5*]
Mo1975. Increased Insertion Time...[4*]
Mo1976. A family history questionnaire...[5*]
Mo1977. Monitoring the Dutch National Colorectal Cancer...[2*]
Mo1978. Temporal Trends in Using Fecal Immunochemical Test...[5*]
Mo1979. Offering colonoscopy to participants...[2*]
Mo1980. FIT-based colorectal cancer screening...[2*]
Mo1981. Sensitivity of annual Faecal Immunochemical Tests...[2*][3*] Eiken Chemical Co. Ltd.
Mo1982. Do men and women need to be screened...[5*]
Mo1983. Seasonal Variation of Colonoscopy Bowel Preparation...[5*]
Mo1984. Third round of two-sample immunochemical...[5*]
Mo1985. PillCam© Colon Capsule for Colorectal Cancer...[3*]
Mo1986. Mean Number of Adenomas Detected...[5*]

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NBI, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds
(5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Year</th>
<th>Title of Study</th>
<th>Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mo1987</td>
<td>Comparison of adenoma detection rate...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1988</td>
<td>Positive predictive value increases...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1989</td>
<td>Increased Incidence of Colonic Adenomas...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1990</td>
<td>The Use of Office-Based M2-PK Stool Test...{(3*) Alere San Diego Inc.}</td>
<td></td>
</tr>
<tr>
<td>Mo1991</td>
<td>Risk factors for the development of sessile serrated polyposis...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1992</td>
<td>Weight or BMI gain in adulthood...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1993</td>
<td>Identification of individuals at high risk...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1994</td>
<td>Colorectal Tumor Testing to Identify Persons...{(7*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1995</td>
<td>Healthcare utilization was an independent predictor...{(4*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1996</td>
<td>Validation of Simulation Models...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1997</td>
<td>Tumor size is a prognostic factor...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1998</td>
<td>Adenocarcinoma of the esophagogastric junction...{(4*)}</td>
<td></td>
</tr>
<tr>
<td>Mo1999</td>
<td>How often does major gastrointestinal bleeding...{(6*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2000</td>
<td>Role of wood stove (fogón) use...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2001</td>
<td>The Impact of Nativity on Gastric Cancer...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2002</td>
<td>Streptococcus bovis Bacteremia...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2003</td>
<td>Long-term prospective observational study...{(3*) Pfizer Inc funded the study. Data were used from Kaiser Permanente.}</td>
<td></td>
</tr>
<tr>
<td>Mo2004</td>
<td>Using Social Media to Advance...{(6*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2005</td>
<td>Incidence of Recurrence of Intestinal Metaplasia...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2006</td>
<td>Risk of Gastrointestinal Cancers in Cystic Fibrosis...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2007</td>
<td>ZBP-89 (ZNF148) Cooperates with HNF1A...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2008</td>
<td>CD14 transcriptional response to vitamin D...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2009</td>
<td>Probe-Based Confocal Laser Endomicroscopy (pCLE)...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2010</td>
<td>Probe-Based Confocal Endomicroscopy...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2011</td>
<td>Novel image of Mitochondria...{(4*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2012</td>
<td>Confocal laser endomicroscopy...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2013</td>
<td>Live, dynamic bioluminescent imaging...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2014</td>
<td>Molecular Targeted Theranostic Photoimmunochemotherapy...{(2*)}<a href="6">(4)</a></td>
<td></td>
</tr>
<tr>
<td>Mo2015</td>
<td>Simultaneous monitoring of contractile activity...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2016</td>
<td>Intra-abdominal adhesions...{(6*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2017</td>
<td>Clinical Study of ex-vivo Photoacoustic Imaging...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2018</td>
<td>Endoscopic ultrasound guided biliary decompression...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2019</td>
<td>Females are more resistant to ischemia-reperfusion...{(7*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2020</td>
<td>Low Pulsatility Index is Associated with...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2021</td>
<td>The Role of Hypercoagulability...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2022</td>
<td>Outcomes in ischemic colitis...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2023</td>
<td>Induction of immunoglobulin A...{(2*)} This study was supported by grant 81270456 and 81171847 from the National Natural Science Foundation of China (to Dr. K-X Liu), and grants S2013010015398 from the National Natural Science Foundation of Guang Dong Province, China (to Dr. Xu-yu Zhang). The authors have no financial conflicts of interest.</td>
<td></td>
</tr>
<tr>
<td>Mo2024</td>
<td>Remifentanil preconditioning protects intestine...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2025</td>
<td>Mir-378 attenuates intestinal ischemia...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2026</td>
<td>Pelvic radiation disease...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2027</td>
<td>Comparison of chronic radiation proctopathy...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2028</td>
<td>A functional approach to improve barrier function...{(4*)}[(2)][(3)] Ente</td>
<td></td>
</tr>
<tr>
<td>Mo2029</td>
<td>Differential activity of NHE3 and NHE2...{(4*)}[(2)][(3) Ente</td>
<td></td>
</tr>
<tr>
<td>Mo2030</td>
<td>Neurobiology of psychological resilience...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2031</td>
<td>Involvement of catechol-O-methyltransferase...{(4*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2032</td>
<td>Down regulation of NMDA receptor signaling...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2033</td>
<td>Marked Elevation in Mucosal Proinflammatory PGE2...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2034</td>
<td>Colonic hypersensitivity induced by chronic stress...{(5*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2035</td>
<td>Regional grey matter properties...{(2*)}[(4) Supported by an unrestricted grant from Danone Research.</td>
<td></td>
</tr>
<tr>
<td>Mo2036</td>
<td>Genome-wide Transcriptional Profiling...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2037</td>
<td>Phosphodiesterase 2A mediates neonatal...{(4*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2038</td>
<td>Early infections and the risk of irritable bowel syndrome...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2039</td>
<td>Colonic mucosa microbiome and host gene expression...{(2*)}[(4)][(7)</td>
<td></td>
</tr>
<tr>
<td>Mo2040</td>
<td>Experimentally induced visceral pain...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2041</td>
<td>Effect of Iobutant, a Neurokinin NK2 Receptor Antagonist...{(2*)}[(3] Funded by NIH R37 DK54824, R01 DK57284, and by Menarini Bicerhe S.p.A., Firenze, Italy</td>
<td></td>
</tr>
<tr>
<td>Mo2042</td>
<td>TNFa in irritable bowel syndrome...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2043</td>
<td>Increased pain hypersensitivity in women...{(4*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2044</td>
<td>Studying mechanically-insensitive colorectal afferents...{(2*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2045</td>
<td>The normoglycemic BB-DP rat...{(4*)}[(2]</td>
<td></td>
</tr>
<tr>
<td>Mo2046</td>
<td>Atopic sensitization and functional gastrointestinal...{(4*)}</td>
<td></td>
</tr>
<tr>
<td>Mo2047</td>
<td>Identifying Functionally Meaningful Biomarkers...{(3*)}[(4)</td>
<td></td>
</tr>
<tr>
<td>Mo2048</td>
<td>Altered Relation of Autonomic Response...{(5*)}</td>
<td></td>
</tr>
</tbody>
</table>

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  (5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
<table>
<thead>
<tr>
<th>Tu1136</th>
<th>Clinical factors predictive of Eosinophilic Esophagitis...</th>
<th>Tu1159</th>
<th>The Learning Curve for Interpretation of Esophageal...</th>
<th>Tu1181</th>
<th>The Induction of Acute Reflux Esophagitis...</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tu1137</td>
<td>Eosinophilic Esophagitis and the Etiology of Food...</td>
<td>Tu1160</td>
<td>Esophagogastric junction distensibility...</td>
<td>Tu1182</td>
<td>High Resolution Esophageal Manometry...</td>
</tr>
<tr>
<td>Tu1138</td>
<td>Awareness and Current Knowledge...</td>
<td>Tu1161</td>
<td>Does an endoscopic submucosal dissection...</td>
<td>Tu1183</td>
<td>The clinical roles of multiple rapid swallow...</td>
</tr>
<tr>
<td>Tu1139</td>
<td>Food Impaction Risk in Adult Patients...</td>
<td>Tu1162</td>
<td>Clinical Features And Outcomes Of Achalasia...</td>
<td>Tu1184</td>
<td>High Resolution Manometry with multiple water swallows...</td>
</tr>
<tr>
<td>Tu1140</td>
<td>Assessment of the Clinical and Allergy Profiles...</td>
<td>Tu1163</td>
<td>Gastroesophageal reflux after peroral endoscopic myotomy...</td>
<td>Tu1185</td>
<td>Community-based Characterization of Esophageal...</td>
</tr>
<tr>
<td>Tu1141</td>
<td>Esophageal body response to volumetric distension...</td>
<td>Tu1164</td>
<td>Upper Esophageal Sphincter Pressure...</td>
<td>Tu1186</td>
<td>The Role of Integrated Relaxation Pressure...</td>
</tr>
<tr>
<td>Tu1142</td>
<td>Esophageal diverticula are associated with...</td>
<td>Tu1165</td>
<td>Clinical and endoscopic characteristics...</td>
<td>Tu1187</td>
<td>Prolonged Intra-Esophageal pH Profile...</td>
</tr>
<tr>
<td>Tu1143</td>
<td>Diagnosis of esophageal motility disorders...</td>
<td>Tu1166</td>
<td>Intubation in Patients with Esophageal food...</td>
<td>Tu1188</td>
<td>GI Problems Associated with Systemic Sclerosis...</td>
</tr>
<tr>
<td>Tu1144</td>
<td>Quantifying Esophageal Bolus Emptying...</td>
<td>Tu1167</td>
<td>Pharmacological Management of Esophageal...</td>
<td>Tu1189</td>
<td>Long-term Esophageal Outcomes of Esophageal Atresia...</td>
</tr>
<tr>
<td>Tu1145</td>
<td>Effects of esophageal capsaicin...</td>
<td>Tu1168</td>
<td>Combined Esophagogastric Junction...</td>
<td>Tu1190</td>
<td>Chronic Pulmonary Disease in Patients...</td>
</tr>
<tr>
<td>Tu1146</td>
<td>Rs4898 is a genetic variation...</td>
<td>Tu1169</td>
<td>Loss of peristaltic reserve determined by...</td>
<td>Tu1191</td>
<td>Impact of Esophageal Motor Diagnoses...</td>
</tr>
<tr>
<td>Tu1147</td>
<td>Acetaminophen has the potential to become...</td>
<td>Tu1170</td>
<td>Younger Male Achalasia Patients...</td>
<td>Tu1192</td>
<td>Reference Values of Esophagogastric Junction...</td>
</tr>
<tr>
<td>Tu1148</td>
<td>Chicago 3.0 classification shows a higher...</td>
<td>Tu1171</td>
<td>Influence of peroral esophageal myotomy...</td>
<td>Tu1193</td>
<td>GI Motility Studies in Lung Transplant Recipients...</td>
</tr>
<tr>
<td>Tu1149</td>
<td>Anxiety and impedance during contraction...</td>
<td>Tu1172</td>
<td>Correlation between High-resolution manometry metrics...</td>
<td>Tu1194</td>
<td>Clinical characteristics associated with function of...</td>
</tr>
<tr>
<td>Tu1150</td>
<td>A Novel Methodology of Measuring...</td>
<td>Tu1173</td>
<td>The Effect of Weak and Failed Peristalsis...</td>
<td>Tu1195</td>
<td>Efficacy of Pneumatic Dilation...</td>
</tr>
<tr>
<td>Tu1151</td>
<td>Increasing Inpatient Burden and Costs...</td>
<td>Tu1174</td>
<td>Correlates of various impaired esophageal motility...</td>
<td>Tu1196</td>
<td>Gastrointestinal (GI) Symptoms in Patients...</td>
</tr>
<tr>
<td>Tu1152</td>
<td>Characterization of Primary Esophagogastric...</td>
<td>Tu1175</td>
<td>High resolution manometry and timed barium swallow...</td>
<td>Tu1197</td>
<td>Flexible endoscopic diverticulectomy of diverticulum...</td>
</tr>
<tr>
<td>Tu1153</td>
<td>Impedance planimetry (EndoFLIP®) measurements...</td>
<td>Tu1176</td>
<td>Esophageal High Resolution Manometry...</td>
<td>Tu1198</td>
<td>A United Kingdom (UK) single-centre 5 year experience...</td>
</tr>
<tr>
<td>Tu1154</td>
<td>Lower esophageal sphincter dilation...</td>
<td>Tu1177</td>
<td>Identification of Hiatal Hernia...</td>
<td>Tu1199</td>
<td>Nutritional status of patients...</td>
</tr>
<tr>
<td>Tu1155</td>
<td>Stress Softening Behavior in the Mucosa-submucosa...</td>
<td>Tu1178</td>
<td>Identification of Hiatal Hernia...</td>
<td>Tu1200</td>
<td>Esophageal Motor Disorders in a Mexican Population...</td>
</tr>
<tr>
<td>Tu1156</td>
<td>Genome-wide expression profiling...</td>
<td>Tu1179</td>
<td>Development of novel treatment...</td>
<td>Tu1201</td>
<td>Effects of Transcutaneous Electrical Acupuncture...</td>
</tr>
<tr>
<td>Tu1157</td>
<td>Esophageal peristaltic reserve in patients...</td>
<td>Tu1180</td>
<td>Even experts have problems with esophageal...</td>
<td>Tu1202</td>
<td>Does realistic clinical acupuncture treatment...</td>
</tr>
<tr>
<td>Tu1158</td>
<td>Impact of Averaged Swallow Sequences...</td>
<td>Tu1181</td>
<td>Does dysphagia in patients...</td>
<td>Tu1203</td>
<td>Duodenal eosinophilia and functional dyspepsia...</td>
</tr>
</tbody>
</table>

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu1263. . . . Transitional care in inflammatory bowel disease...[5*]

Tu1264. . . . Intolerance of Uncertainty and Quality of Life...[3*] AbbVie

Tu1265. . . . Inflammatory Bowel Disease Patient’s Participation...[5*]

Tu1266. . . . Response to the Specific Carbohydrate Diet...[5*]

Tu1267. . . . The effects of infliximab treatment failure...[6*]

Tu1268. . . . Effect of vedolizumab on health-related quality of life...[3*] The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).

Tu1269. . . . Psychological Profiling In Crohn’s Disease...[4*]

Tu1270. . . . Characterization of Variables impacting on the Quality...[6*]

Tu1271. . . . An Inflammatory Bowel Disease Patient’s Worst Fears...[5*]

Tu1272. . . . Psychological characteristics and daily abdominal pain...[5*]

Tu1273. . . . Where do patients go for information...[1*][3] Warner Chilcott provided a research grant covering printing and postage costs.

Tu1274. . . . The influence of different information sources disease...[1*][3] Warner Chilcott provided a research grant covering printing and postage costs.

Tu1275. . . . Assessment of health-related quality of life...[5*]

Tu1276. . . . Validation of a self-reported Ulcerative Colitis...[1*]

Tu1277. . . . Serum TNF levels influence post-induction...[4*]

Tu1278. . . . Infliximab and adalimumab serum levels...[4*]

Tu1279. . . . Biomarkers predict lack of response...[5*]

Tu1280. . . . Antibodies to infliximab, body weight and low serum...[5*]

Tu1281. . . . The antimicrobial peptide expression...[2*][4][6]

Tu1282. . . . Azathioprine or 6-mercaptopurine dose...[5*]

Tu1283. . . . Proteolytic stability of AVX-470...[3*] This study was internally funded by Avaxia Biologics.

Tu1284. . . . Characterisation of inflammatory phenotype...[6*]

Tu1285. . . . Relationship between measures of infliximab exposure...[6*]

Tu1286. . . . Early therapeutic drug monitoring...[7*]

Tu1287. . . . Capability of fecal calprotectin to detect...[5*]

Tu1288. . . . The Predictive Value of Early Serum Infliximab...[4*]

Tu1289. . . . Preventing Crohn’s Disease Recurrence...[5*]

Tu1290. . . . Using a pharmacokinetic dashboard to forecast...[4*]

Tu1291. . . . Infliximab serum levels do not predict remission...[5*]

Tu1292. . . . Quantification of the concentration of antibodies...[5*]

Tu1293. . . . Soluble tnf serum levels during the induction...[5*]


Tu1295. . . . Effect of Vedolizumab on Circulating Lymphocyte Subsets...[4*]

Tu1296. . . . P-glycoprotein 170 (p-gp) functional activity...[3*] Investigator Initiate Study AbbVie

Tu1297. . . . Penetration of AVX-470...[3*] Financial support for this study came from Avaxia Biologics, Inc.

Tu1298. . . . Anti-infliximab antibodies with neutralizing capacity...[6*]

Tu1299. . . . Higher adalimumab drug levels are associated with...[5*][3]

Tu1300. . . . Mucosal drug concentration and clinical characteristics...[4*]

Tu1301. . . . Validation of a homogenous mobility shift assay (HMSA)...[3*] Prometheus Laboratories, A Nestle Health Sciences Company

Tu1302. . . . Anti-TNF-a induction regimen modulates...[5*]

Tu1303. . . . Anti-TNF-mediated Prohepcidin modulation...[4*]

Tu1304. . . . Faecal calprotectin measurement and infliximab...[1*]

Tu1305. . . . Analysis of Outcomes After Non-Medical Switching...[3*] Design, study conduct, and financial support for the study were provided by AbbVie Inc. AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication and maintained control over the final content. Medical writing support was provided by Cathryn M. Carter, MS, of Arbor Communications, Inc; this support was funded by AbbVie.

Tu1306. . . . Clinical Outcomes Associated With Switching...[3*] Design, study conduct, and financial support for the study were provided by AbbVie Inc. AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication and maintained control over the final content. Medical writing support was provided by Cathryn M. Carter, MS, of Arbor Communications, Inc; this support was funded by AbbVie.

Tu1307. . . . Using serum infliximab drug and TNF cytokine...[4*] Prometheus Labs performed all assays.

Tu1308. . . . Adequate Trough Concentrations and Sustained TNF...[2*]

Tu1309. . . . A checklist improves vaccination, health maintenance...[5*]

Tu1310. . . . Treatment of Infliximab or Adalimumab...[4*]

Tu1311. . . . Validation of a homogenous mobility shift assay...[3*] Prometheus Laboratories, A Nestle Health Sciences Company

Tu1312. . . . Low Infliximab trough levels are not predictive...[4*]

Tu1313. . . . Infliximab is more effective than azathioprine...[5*]

Tu1314. . . . Outcome measures of rescue therapy with infliximab...[5*]

Tu1315. . . . Loss of response in IBD patients on infliximab treatment...[4*]

Tu1316. . . . Dose optimization of Infliximab...[4*][3] Prometheus Labs (California, USA) provided the homogenous mobility shift assays used.

Abstract Funding Source Key
* = Primary Source
(1) = Clinical Practice Funds  (2) = Government (e.g. NBI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFRA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Factors of JCV virus in a large cohort of IBD patients

Exposure to Certolizumab Pegol

Thiopurine response and shunter status

Levels and shunter status

Predictors and outcomes of new-onset liver enzyme elevations

Efficacy of thiopurines in achieving mucosal healing

Cost per Remitted Associated With Biologic Therapies

Financial support for the study and medical writing support (Tonya Goodman, Arbor Communications, Ann Arbor, MI) was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content.

Topical administration of adalimumab drug levels

Hyperbaric Oxygen Therapy in the management

Combination therapy with infliximab and azathioprine

Early treatment with infliximab

Long-term outcome of IBD patients

Seroprevalence and risk factors of JC virus

Paradoxical psoriasis in a large cohort of IBD patients

Pregnancy Outcomes after Exposure to Certolizumab Pegol

Tu1319. Paradoxical psoriasis in a large cohort of IBD patients

Tu1320. Pregnancy Outcomes after Exposure to Certolizumab Pegol

Tu1321. Systematic Review with Meta-analysis of Prospective Studies

This study was financially supported in part by National Key Clinical Department in Ministry of Public Health, China (No.2011YZ-00004).

Tu1322. A prospective evaluation of drug levels

Tu1323. Utility and Reproducibility of a Cut-Off Value

Tu1324. Unfavorable initial thiopurine response

Tu1325. Therapeutic Cut-off of Infliximab in Patients

Tu1326. Topical administration of the Toll-like receptor

Tu1327. Factors Associated with Achievement of Mucosal Healing

Tu1328. Final Thiopurine Metabolite Levels and Shunter Status

Tu1329. IBD Patients Taking Thiopurine Medications

Tu1330. Thiopurine metabolite testing to guide management

Tu1331. Are we under-recognizing skewed thiopurine metabolism

Tu1332. Exploring the Efficacy of Weight-Based Dosing

Tu1333. Cyclosporine therapy as a rescue treatment

Tu1334. Long-term outcome of IBD patients

Tu1335. Predictors and outcomes of new-onset liver enzyme elevations

Tu1336. Cost per Remitted Associated With Biologic Therapies

Tu1337. Anti-TNFa treatment efficacy in prevention

Tu1338. Inflammatory Bowel Disease Provoked by Etanercept

Tu1339. Mucosal and histologic response to cyclosporin

Tu1340. Hyperbaric Oxygen Therapy in the management

Tu1341. Combination therapy with infliximab and azathioprine

Tu1342. Early treatment with infliximab

Tu1343. Long-term outcome of IBD patients

Tu1344. Serology panel for prediction of relapse

Tu1345. Efficacy and safety of anti-TNF therapy

Tu1346. Skin and joint side effects in a subgroup

Tu1347. Response to Anti-TNF Therapy in Hispanics

Tu1348. Biosimilar infliximab in inflammatory bowel diseases

Tu1349. The Efficacy and Safety of Calcineurin Inhibitors

Tu1350. Vedolizumab in the Treatment of IBD

Tu1351. Crohn's Disease Patients Currently or Previously

Tu1352. Use of complementary alternative medicine

Tu1353. Efficacy of Thiopurines in Achieving steroid free

Tu1354. Efficacy of thiopurines in achieving mucosal healing

Tu1355. Pharmacokinetics of Certolizumab pegol

Tu1356. Efficacy of Certolizumab Pegol

Tu1357. Antiplatelet Therapy with Aspirin and Clopidogrel

Tu1358. Novel Technique for Gastrointestinal Fluid Isolation

Tu1359. Efficacy of vedolizumab as induction therapy

Tu1360. Fecal microbiota transplantation is safe and effective

Tu1361. Intestinal Microbiome Restoration for Recurrent

Tu1362. The Clinical Course of Ulcerative Colitis Patients

Tu1363. An Open-label, Pilot Study to Assess Feasibility

Tu1364. Treatment with Anakinra

Tu1365. Low dose Naltrexone in the Treatment of Crohn's

Tu1366. Tacrolimus therapy for outpatients

Tu1367. Effectiveness and Safety of Certolizumab Pegol

Tu1368. Vedolizumab in inflammatory bowel disease

Tu1369. Vedolizumab efficacy and safety

Tu1370. Efficacy of Adalimumab (ADA) therapy

Tu1371. A Retrospective Review of Response Rates

Tu1372. Efficacy of Exclusive Enteral Nutrition

Tu1373. Increase of CUGBP1 induced by

Tu1374. 1,25-Dihydroxyvitamin D3 preserves

Tu1375. Krüppel-like Factor 5 (KLF5) regulates

Abstract Funding Source Key

* = Primary Source

(1) = Clinical Practice Funds  (2) = Government (e.g. NHI, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity  (4) = Institutional Funds  
(5) = No Study Funding  (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.)  (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Abstract Funding Source Key

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CFIA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)

Tu1376. Protective effects of Partially Hydrolyzed Guar Gum...[5*]

Tu1377. Rapid Disruption of Colonic Epithelial Tight Junctions...[2*]

Tu1378. The protective effects of partially hydrolyzed guar gum...[2*]

Tu1379. 13C Mannitol as a novel biomarker...[4*]

Tu1380. Fistulising Perianal Crohn's Disease...[4*]

Tu1381. Genome-wide association identifies...[5*]

Tu1382. The role of NHE8 in intestinal mucosal Homeostasis...[2*]

Tu1383. Serologic and Genetic Markers may Predict...[6*]

Tu1384. Meconium Ileus: Mucin Secretion...[2*]

Tu1385. Functional Gastrointestinal Disorders...[2*]

Tu1386. Systematic Genomic Characterization of Normal Mucosa...[2*]

Tu1387. Exploration of genetic basis of Inflammatory...[5*]

Tu1388. Diverticular Disease and Chronic Inflammation...[1*]

Tu1389. Increased Basolateral Small Conductance Potassium Channel...[6*]

Tu1390. Anocutamin 6 Contributes to Accessory Chorera Enterotoxin...[4*]

Tu1391. Different Dosing Regimens Modify Ion Transport...[3*][2] Ferring Research Institute Inc.

Tu1392. Altered crypt formation and hydrogen peroxide transport...[2*]

Tu1393. Na/K-ATPase inhibition uniquely regulates...[2*]

Tu1394. PDZK1 expression is critical...[2*]

Tu1395. Gene expression of intestinal ion...[2*][4]

Tu1396. Acquisition by the residual colon...[2*][4] Bioscophex

Tu1397. Somatostatin regulates NHE8 protein...[4*]

Tu1398. Direct and specific inhibition of constitutive...[2*]

Tu1399. The bile acid (BA), lithocholic acid (LCA)...[2*][4]

Tu1400. Angiotensin II Decreases P-glycoprotein...[2*]

Tu1401. Differential Intracellular Calcium Inhibition...[2*]

Tu1402. All-trans retinoic acid (ATRA) Stimulates...[2*]

Tu1403. Neural FFA3 activation inversely regulates...[2*]

Tu1404. Lactobacillus acidophilis Attenuates Inhibition...[2*]

Tu1405. Apolipoprotein-AV Resists Proteolysis...[2*]

Tu1406. Effect of Induced Ischemia on intestinal fluid secretion...[4*]

Tu1407. Catherer Angulation and Pressure Are Major Determinants...[4*]

Tu1408. EGJ relaxation during sitting MRS...[4*]

Tu1409. Incomplete LES relaxation might be the primary...[5*]

Tu1410. The cytokine expression patterns...[4*]

Tu1411. Beneficial effect of long-term buspirone...[5*]

Tu1412. Esophageal motility of patients...[2*]

Tu1413. Relationship between esophageal pressure...[5*]

Tu1414. Evaluation of Transit Patterns...[5*]

Tu1415. Achalasia in Evolution...[5*]

Tu1416. Swallow-Related Axial Shortening...[2*]

Tu1417. An Epidemiological Study on Esophageal Symptoms...[2*]

Tu1418. Physiologic esophageal length in adults...[5*]

Tu1419. High resolution esophageal manometry in pediatric achalasia...[5*]

Tu1420. Peristalsis Recovery After Peroral Endoscopic Myotomy...[4*]

Tu1421. Complications of Botulinum Toxin...[5*]

Tu1422. Questioning the significance of large and small breaks...[5*]

Tu1423. Impact of rapid swallows and solid swallows...[5*]

Tu1424. Pressure Drift Correction in Prolonged...[2*]

Tu1425. The Effects of Body Position...[2*]

Tu1426. Differences in the control of distension-induced...[5*]

Tu1427. Neuromuscular Evaluation of Drug and Device...[1*]

Tu1428. Using the Rome III Criteria to Diagnose...[5*]

Tu1429. Is Proton Pump Inhibitor Use Associated with...[2*][3] Forest Pharmaceuticals provided the escitalopram and identical placebo for the study.

Tu1430. Functional Dyspepsia Treatment Trial...[2*][3] Forest Pharmaceuticals provided the escitalopram and identical placebo for the study.

Tu1431. Impaired Quality of life in patients with Belching...[3*] ASOFARMA de Mexico

Tu1432. Dyspeptic symptoms and its impact on quality of life...[3*] ASOFARMA de Mexico

Tu1433. Alternations of Interleukin families...[4*]

Tu1434. Duodenal Acid Perfusion In Healthy Volunteers...[4*]

Tu1435. Functional Dyspepsia Treatment Trial (FDTT)...[2*][3] Forest Pharmaceuticals provided the escitalopram and identical placebo for the study.

Tu1436. Acotiamide improves stress-induced...[4*]

Tu1437. Randomized clinical study on functional dyspepsia...[5*]

Tu1438. Efficacy of DA-9701 (Motilitone)...[3*] Dong-A ST Co., LTD.

Tu1439. African American race and chronic opiate use...[5*]

Tu1440. Discovering new underlying mechanisms...[3*] Steigerwald Arzneimittelwerk GmbH, GmbH, Darmstadt, Germany
Tu1441. . . . . . The Effect of DA-9701 (Motilitone)...(3*)
Tu1442. . . . . . Moderate to severe dyspepsia in multiple sclerosis...(5*)
Tu1443. . . . . . The Optimum Acceptable Swallowing Rate...(5*)
Tu1444. . . . . . Mechanism of rikkunshito-induced gastric relaxation...(3*) Tsumura & Co.
Tu1445. . . . . . High Resolution Esophageal Manometry Pattern in Children...(5*)
Tu1446. . . . . . Functional dyspepsia is associated with lower exercise levels...(3*) This study was supported by Janssen as an investigator Initiated Study.
Tu1447. . . . . . A rodent model of impaired gastric motility...(2*)
Tu1448. . . . . . Gabapentin/Pregabalin improves symptoms...(5*)
Tu1449. . . . . . Stress and stress-related peptide amplify...(4*)
Tu1450. . . . . . Aberrant Swallow: Swallow Without Pharyngeal Contractile...(4*)
Tu1451. . . . . . Correlative patterns of upper esophageal sphincter contractility...(4*)
Tu1452. . . . . . Dynamics of pharyngeal contraction...(2*)
Tu1453. . . . . . Pharyngeal Bolus Transit in a Human Model...(2*)
Tu1454. . . . . . Inter-rater Agreement for Analysis of Pharyngeal...(2*)
Tu1455. . . . . . Pharyngeal Stimulus Induced Reflexes...(2*)
Tu1456. . . . . . Effect of Postmenstrual Age (PMA)...(2*)
Tu1457. . . . . . The safety of gastrointestinal endoscopy...(5*)
Tu1458. . . . . . The outcome of gastrointestinal endoscopy...(5*)
Tu1459. . . . . . Pharyngeal Pressure Metrics Following Total Laryngectomy...(4*)
Tu1460. . . . . . Custom Dietary Interventions by a Multi-Disciplinary...(3*) Abbott and Baxter
Tu1461. . . . . . The Impact of Home Parental Nutrition on Employment...(5*)
Tu1462. . . . . . A large US referral center experience...(5*)
Tu1463. . . . . . Failure of oral intake to meet nutritional requirements...(2*)(3) Nutricia
Tu1464. . . . . . Retrospective cohort study of the clinical outcome...(5*)
Tu1465. . . . . . Percutaneous Endoscopic Gastrostomy Tube...(9*)
Tu1466. . . . . . Improvement in glucose metabolism...(5*)
Tu1467. . . . . . Spatz Adjustable Balloons...(5*)
Tu1468. . . . . . A Pre-clinical Animal Study Evaluating the Feasibility...(4*)
Tu1469. . . . . . First prospective endoscopic sleeve gastroplasty study...(5*)
Tu1470. . . . . . Interim results of a multi-center, prospective...(2*)
Tu1471. . . . . . A new approach in the treatment of Weight Regain...(1*)
Tu1472. . . . . . Intra-gastric Balloon as a Treatment Method...(1*)
Tu1473. . . . . . Transoral outlet reduction (TORe) versus...(5*)
Tu1474. . . . . . Reduced 2-Hydroxybutyric Acid...(2*)
Tu1475. . . . . . Endoscopic Sleeve Gastroplasty: Mid-term Results...(5*)
Tu1476. . . . . . Rapid increase of glucose consumption...(2*)
Tu1477. . . . . . Intragastric Balloons Are Effective at Inducing Weight Loss...(5*)
Tu1478. . . . . . Risk Factors Associated with Post-operative...(5*)
Tu1479. . . . . . Determining Optimal Timing for Aspiration...(3*) ASPIRE Bariatrics, King of Prussia, PA 19406 USA
Tu1480. . . . . . Treatment of sleeve gastrectomy strictures...(5*)
Tu1481. . . . . . A Pilot Study to Assess the feasibility...(5*)
Tu1482. . . . . . Autoimmune Pancreatitis: Variable response...(5*)
Tu1483. . . . . . Anti-PBP antibodies not useful...(5*)
Tu1484. . . . . . Serum IgG4 in acute, chronic and autoimmune pancreatitis...(5*)
Tu1485. . . . . . Azathioprine maintenance therapy to prevent relapses...(5*)
Tu1486. . . . . . Mortality in patients with chronic pancreatitis...(5*)
Tu1487. . . . . . Endoscopic ultrasound (EUS)-based multimodal evaluation...(5*)
Tu1488. . . . . . The Effect of Cold Ischemia Time on Islet Cell Function...(5*)
Tu1489. . . . . . Correlation between pancreatic exocrine function...(5*)
Tu1490. . . . . . Serum Amylase and Lipase Levels...(1*)
Tu1491. . . . . . Duct diameter and Size of Stones...(5*)
Tu1492. . . . . . Characteristics and Predictors of Large Duct...(5*)
Tu1493. . . . . . Single versus multiple pancreatic stents...(5*)
Tu1494. . . . . . Low early pancreatic volume reduction...(5*)
Tu1495. . . . . . Hereditary Pancreatitis in children...(4*)
Tu1496. . . . . . Treatment Strategy for Chronic Pancreatitis...(4*)
Tu1497. . . . . . Risk Factors and Disease Burden...(2*)
Tu1498. . . . . . Increased awareness enhances physician recognition...(2*)
Tu1816. . . . . . 1,25-Dihydroxyvitamin D protects intestinal...(2*)
Tu1817. . . . . . Impaired Mitochondrial Function Inhibits...(2*)
Tu1818. . . . . . Dual protections of intracellular heat shock protein...(2*)(4)
Tu1819. . . . . . C-Jun N-terminal kinases 2 in non-hematopoietic...(4*)
Tu1820. . . . . . Loss of intestinal Desmoglein 2...(4*)
Tu1821. . . . . . Long Non-Coding RNAs in IBD...(6*)
Tu1822. . . . . . Deletion of Rho-A within IECs...(2*)(4)
Tu1823. . . . . . Elevated expression of colonic CYP3A4...(2*)

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds   (2) = Government (e.g. NIH, CDC, Health Ministry, etc.)  (3) = Industry or Commercial Entity   (4) = Institutional Funds
(5) = No Study Funding   (6) = Philanthropic Organization (e.g. ALF, CCF, etc.)   (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Cells Tu1824. . . . . . . Targeting Intestinal Stem Cells...([2],[4])
Tu1825. . . . . . . . . . . . . CAP-D3 promotes bacterial clearance...([2],[4])
Tu1826. . . . . . . . . . . . . Lgr5+ stem cells contribute to fibrogenesis...([2])
Tu1827. . . . . . . . . . . . . Low mitochondrial activity within intestinal inflammation...([2],[4])
Tu1828. . . . . . . . . . . . . Loss of Syndecan-1 by upregulation...([2])
Tu1829. . . . . . . . . . . . . Discovery of an epithelial form of elastase...([2])
Tu1830. . . . . . . . . . . . . Short-term regulation of Na+/H+ Exchanger...([4])
Tu1831. . . . . . . . . . . . . Loss of integrin b6 (ITGB6) results in...([5])
Tu1832. . . . . . . . . . . . . Homeostatic regulation of Laminitin y2 expression...([4])
Tu1833. . . . . . . . . . . . . Dipotassium Glycyrrhizate Affects...([4])
Tu1834. . . . . . . . . . . . . MiR-19b modulates intestinal epithelial cell...([2])
Tu1835. . . . . . . . . . . . . Inflammatory cells enhance defensin expression...([4])...([2])
Tu1836. . . . . . . . . . . . . Identification of DSG3, MAGI1 and TFF1...([4])
Tu1837. . . . . . . . . . . . . Continuous stimulation with cytokines...([2])
Tu1838. . . . . . . . . . . . . Gene Expression in Luminal Extracellular Vesicles...([5])
Tu1839. . . . . . . . . . . . . Pulse Wave Velocity, Intima Media Thickness...([5])
Tu1840. . . . . . . . . . . . . Protective role of uric acid excretion...([5])
Tu1841. . . . . . . . . . . . . Investigation of indomethacin-induced...([5])
Tu1842. . . . . . . . . . . . . Intestinal manipulation-induced monocyte...([2])
Tu1843. . . . . . . . . . . . . Colchicine prevents NSAIDs-induced...([2])
Tu1844. . . . . . . . . . . . . Geranylgeranylation protects against small-intestinal...([3])

Abstract Funding Source Key

* = Primary Source
(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
| Tu1886 | Adipose tissue is toxic for pancreatic parenchyma... | Tu1887 | MicroRNAs profiles of mouse acinar cells... | Tu1888 | Proteome mouse strain differences... | Tu1889 | Administration of Witahaerin A Protects Mice... | Tu1890 | Involvement of Heparanase in the Pathogenesis... | Tu1891 | Feasibility of non-invasive method... | Tu1892 | Involvement of the calcium-binding protein... | Tu1893 | Lyn is a key regulator of stellate cell chemotaxis... | Tu1894 | Chronic pancreatitis occurs in obese rats... | Tu1895 | BACH2 repression enhances Th17 cell axis... | Tu1896 | Aminar-immune interactions in human acute pancreatitis... | Tu1897 | Pharmacologic Attenuation of NF-kB Activity... | Tu1898 | CSF1-R inhibition alters macrophage function... | Tu1899 | Gastric Acid Secretion via the H+ATPase... | Tu1900 | Ghrelin resistance is associated with anorexia... | Tu1901 | Bile acid cocktail induces similar changes... | Tu1902 | Characterization of Inducible BMPR2... | Tu1903 | Potentiating Interactions Between Type-3 Mucaricin Receptor... | Tu1904 | BPC 175 attenuates intestinal ischemia/reperfusion injury... | Tu1905 | β-catenin complexes in colorectal cancer... | Tu1906 | Direct activation of MEK1 kinase by Rho kinase ROCK2... | Tu1907 | Curcumin reduces the inflammatory factors... | Tu1908 | Differential expression and tumorigenic function... | Tu1909 | Regulation of glucose metabolism... | Tu1910 | The BARH1 Gene Is Silenced by... | Tu1911 | A novel mechanism for radiocontrast-induced... | Tu1912 | Urocortin 1-induced anorexia is mediated... | Tu1913 | Analysis of molecular features... | Tu1914 | A Case of Duodenal Gastrinoma Associated with... | Tu1915 | The role of combination of molecular imaging studies... | Tu1916 | Discordance in tumor grade between primary and metastatic... | Tu1917 | Analysis of molecular features... | Tu1918 | Correlation between the 18F-FDG uptake... | Tu1919 | A Case of Duodenal Gastrinoma Associated with... | Tu1920 | The role of combination of molecular imaging studies... | Tu1921 | Extraneal marginal zone B-cell lymphoma of MALT... | Tu1922 | Expression of somatostatin receptor... | Tu1923 | Long-term Survival Data in Progressing... | Tu1924 | Epidemiological Characteristics from a Single Centre... | Tu1925 | Diagnosis and treatment of carcinoid tumors... | Tu1926 | A Case of a Rare Type of Aggressive Duodenal Neoplasm... | Tu1927 | An unusual case of headaches and ophthalmoplegia... | Tu1928 | Complications of metal versus plastic stents... | Tu1929 | Alcohol Consumption and Gallbladder Cancer Risk... | Tu1930 | Novel prognostic biomarkers in patients... | Tu1931 | Celecoxib and celecoxib-eluting membrane inhibit... | Tu1932 | CCL1 antisense ODN gene therapy for monocytes... | Tu1933 | The characterization, addressing, and effects of Caco2BBe... | Tu1934 | Chemoradiation-related lymphopenia as an independent... | Tu1935 | Paraneoplastic thrombocytosis independently... | Tu1936 | Undifferentiated Carcinoma with Osteoclast-Like Giant Cells... | Tu1937 | Clinical significance of extended pancreatectomy... | Tu1938 | Predictors of Interobserver Variability... | Tu1939 | A retrospective single center analysis of survival... | Tu1940 | Pancreas cancer in... | Tu1941 | Opium use and Risk of Pancreatic Cancer... | Tu1942 | hENT1 testing in pancreatic ductal adenocarcinoma... | Tu1943 | Can Metformin Change the Prognosis of Pancreatic Cancer?... | Tu1944 | Mutational analysis of pancreatic neuroendocrine tumor... | Tu1945 | CdSe/ZnS quantum dots induce photodynamic effects... | Tu1946 | Correlation of endobiliary brush cytology... | Tu1947 | Cumulative Epigenetic Alterations... | Tu1948 | Initial Metastatic Site as A Prognostic Factor... | Tu1949 | Escaping of ATP-binding cassette sub family... | Tu1950 | Psychological distress and its impact... | Tu1951 | Pancreatoblastoma in an Adult... | Tu1952 | Survival Analysis of Veteran Patients... | Tu1953 | nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone... | 

**Abstract Funding Source Key**

* = Primary Source

(1) = Clinical Practice Funds (2) = Government (e.g. NIH, CDC, Health Ministry, etc.) (3) = Industry or Commercial Entity (4) = Institutional Funds (5) = No Study Funding (6) = Philanthropic Organization (e.g. ALF, CCFA, etc.) (7) = Professional Organization (e.g. AGA, AASLD, etc.)
Tu2021. . . . . . . High-Throughput Analyses of Liver Nucleic Acids...[4*]

Tu2022. . . . . . . Twelve Week Storage Trial of Microbial Viability...[1*](4)

Tu2023. . . . . . . Alcohol Consumption Does Not Increase Risk...[5*]

Tu2024. . . . . . . A Comparison of the Microbiota in Healthy Subjects...[7*]

Tu2025. . . . . . . Fecal Microbiota Transplantation in Irritable Bowel...[1*]

Tu2026. . . . . . . Characterization of Hepatocellular Carcinoma...[5*]

Tu2027. . . . . . . Endoscopic versus Percutaneous Drainage...[5*]

Tu2028. . . . . . . Pentadecapeptide BPC 157 after 70% liver resection...[2*]

Tu2029. . . . . . . Recent Causes of Hepatocellular Carcinoma...[5*]

Tu2030. . . . . . . Predictors of malignancy in biliary mucin-producing...[5*]

Tu2031. . . . . . . Cohort Identification of Hepatocellular Adenoma...[5*]

Tu2032. . . . . . . Can endoscopic ultrasound-guided fine needle aspiration...[5*]

Tu2033. . . . . . . The Use of A Genetic Database...[5*]

Tu2034. . . . . . . FISH, Stents, and Cancer...[5*]

Tu2035. . . . . . . Comparison of Hepatocellular Carcinoma...[5*]

Tu2036. . . . . . . The Role of Chitosan Nanoparticles...[5*]

Tu2037. . . . . . . Des-g-carboxy prothrombin (DCP) is induced...[5*]

Tu2038. . . . . . . Oxidative stress balance is dysregulated...[5*]

Tu2039. . . . . . . Prognostic Indicators in Hilar Cholangiocarcinoma...[5*]

Tu2040. . . . . . . Preventive surveillance in patients...[5*]

Tu2041. . . . . . . As an independent prognostic factor, UBE2T promotes...[2*]
This work was supported by the National Nature Science Foundation of China (Grant Nos. 81172056, 81172586, 81401180 and 81372285).

Tu2042. . . . . . . Entecavir reduces hepatocarcinogenesis...[5*]

Tu2043. . . . . . . Overexpression of NKX6.1 contributes to...[2*]

Tu2044. . . . . . . Protective effects of the prostaglandin I2-IP signal...[2*]

Tu2045. . . . . . . Loss of hepatocyte-specific vascular endothelial growth...[2*]

Tu2046. . . . . . . Early compensatory mechanism of the liver...[2*]

Tu2047. . . . . . . Presence of Diabetes and Chronic Liver Disease...[4*]

Tu2048. . . . . . . Early Palliative Care Consultation...[5*]

Tu2049. . . . . . . Projection of Health Outcomes...[3*] This study was supported by Gilead Sciences, Inc., Foster City, CA, USA.

Tu2050. . . . . . . Predictors of Inpatient Mortality...[5*]